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ABSTRACT
Despite the amount of ongoing intensive research, tumor cells have continued to outwit us in the
effort to combat and prevent cancer by exerting a number of mechanisms to evade and suppress
anti-tumor immune responses. The present work employs strategies to generate a synthetic
extranodal immunoplatform that can harbor both exogenously provided and endogenously
recruited immune cells (primed against tumor cells), at the same time providing immuno-factors
that support these cells and counter immunosuppressive effects from tumors. We have
developed injectable self-gelling alginate formulations for this purpose, enabling sustained
release of soluble immunomodulatory factors from the gels and presentation of immobilized
immunostimulatory factors inside the gels. The hydrogels injected into the back flanks of mice
formed a macroporous structure that allowed easy cell infiltration and migration. Modulation of
the mechanical properties of self-gelling alginate was possible by varying the number of
calcium-bound microspheres in the gels. During characterization of immune responses using
these hydrogels, alginate gels carrying activated dendritic cells (DCs) were shown to
dramatically increase the number of T cells recruited to the local injection site. When the
dendritic cells were pulsed with antigen, these 'vaccination nodes' were able to initiate an
antigen-specific immune response, with some of the injected DCs migrating to the regional
lymph nodes and priming cognate T cells. The activated antigen-specific T cells then migrated
to the injection site and infiltrated the gels, causing an effector re-trafficking phenomenon that
guided both T cells and host dendritic cells to the gels. Taking advantage of this phenomenon,
the ability of the vaccination nodes to serve as a peri-tumoral local therapy against established
tumors was tested using an ovalbumin-expressing B16FO subcutaneous melanoma model. When
mice bearing 7-day established small tumors (-3mm 2 diameter) were immunized using alginate
carrying activated DCs, a mild tumor suppression effect was observed. The anti-tumor effect
was augmented by supplementing IL-15 superagonist (IL-15SA) into the gels, which caused
suppression of larger tumors (-20-50mm2), treated 14 days after tumor cell inoculation, and
enhanced survival of the mice. In addition to showing therapeutic benefits against established
tumors, the matrix-based approach allowed analysis of cells that trafficked locally near the tumor
site. The ease of encapsulating factors and the injectable, non-invasive nature of the self-gelling
alginate open up possibilities for use in other tissue engineering and regenerative medicine
applications.
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Chapter 1
Introduction and Motivation
Standing at the interface of materials engineering and immunology, the thesis work presented
here seeks to fill in some of the gaps that currently exist in cancer immunotherapy, by using
injectable polymeric hydrogels to create a synthetic inflammatory milieu to foster anti-tumor
immunity. An efficient immune response requires a fine-tuned orchestration of factors and
immune cells at the right moments in the right sequence. By providing a synthetic inflammatory
microenvironment that cells can utilize to mount an anti-tumor immune response directly at
tumor sites, via delivery of key immune cells (i.e. dendritic cells) and sustained release of anti-
tumor factors, we hope to support and guide the responses against malignant tumor cells. This
thesis work describes the development and characterization of the injectable hydrogel materials,
their role in generating and modulating antigen-specific immune responses when encapsulating
and delivering dendritic cells, and their application to tumor thepary.
1.1 Cancer Immunotherapy
1.1.1 Conventional treatments ofcancer
Cancer is an uncontrolled and abnormal growth and alterations of otherwise healthy, normal
cells in the body, and such malignant neoplasms consist one of the leading causes of deaths in
the United States as well as all over the world (1). Conventional methods of treatments for
cancer so far have mostly involved external interventions, such as surgery, radiation therapy, and
chemo-therapy, in an attempt to remove and reduce cancerous cells and surrounding tissues as
well as lymph nodes that may be affected. For example, taking advantage of the tumor's high
chemosensitivity, multiple drugs have been developed against ovarian cancer (2). Treatment of
colon cancer often involves surgical removal of polyps in the colon (2). Solid tumors are usually
responsive to radiation therapy (3), which is also used for late stage melanoma patients as a
palliative treatment(4). However, despite the increased detection accuracy and application of the
above mentioned treatments, the battle against cancer still remains a war not yet won (5). One of
the limitations of cancer therapy based on conventional interventions is that the body itself is
unprotected from future recurrences, and treatment of primary as well as metastatic tumors
becomes difficult when tumors are not easily accessible by surgery. As a result, cancer
immunotherapy, utilizing the body's own immune system to reject cancer and create a systemic
protective immunity within the host's body, has become an intensively researched cancer therapy
strategies in recent years. Ideally, immunotherapy not only treats the existent, detectable tumors
but also generates a systemic memory of tumor antigens to protect against recurrence as well as
to eradicate metastatic malignancies.
1.1.2 Role of the immune system in responses against tumors
Tumor immunotherapy relies on the ability of the body's immune system to recognize
cancerous cells as a danger. The potential of the immune system to fight against cancer was first
observed in 1890 by William Coley, when inoperable sarcoma patients were successfully treated
by injection of Streptococcus erysipelas bacterial cultures (6). Increased incidences of cancer in
immunocompromised hosts (7-9) as well as mice lacking specific sets of immune cells, including
T cells, natural killer (NK) cells, and NK T cells (10-12), and other immune-related factors, such
as interferon-y (IFN- y; a cytokine that increases the killing capacity of cytotokic CD8+ T cells)
(11, 13-16) and perforin (a cytolytic granule in T cells and NK cells that participate in cytolytic
killing of target cells) (17-19) , and spontaneous disappearance of malignancies in
immunocompetent patients also point to the importance of the immune cells in controlling
cancerous growths (20). The idea that components of the immune system are capable of fighting
against cancer is called cancer immunosurveillance (21-23). The presence of tumor-infiltrating
lymphocytes (TILs), such as CD8 T cells (24, 25) and NK cells (26-28), in cancer patients has
been demonstrated to be a favorable prognosis of the survival of the patients. Other cell types
that are known to be important for tumor suppression and eradication include dendritic cells (29,
30), CD4+ T cells (31), and interferon-producing killer dendritic cells (IKDCs) (32, 33).
Under ideal situations, an anti-tumor immune response would involve antigen presenting cells
(APCs), particularly dendritic cells, recognizing the tumors as a danger and activating the
cognate oncoantigen-specific T cells (Figure 1-1). Tumor antigens are believed to either drain to
the lymph nodes via lymphatics or be picked up by dendritic cells and brought to the lymph
nodes (34). CD8+ cytolytic T-cells (CTLs) activated in the lymph nodes by dendritic cells would
then migrate to the tumor site and kill the tumor cells, mainly via degranulation of cytotoxins
such as perforin and granulysin. CD4+ T cells both help regulate and maintain the CD8+ T cell
response (35, 36) as well as actively participate in the anti-tumor immune response by secreting
cytokines that activate both Thl (proinflammatory response against intracellular pathogens) and
Th2 responses (allergic responses that mainly involve eosinophils) (31). The innate arm of the
immunity also plays an important role in responses against cancer; immunosurveillance by NK
cells involves degranulation of perforin, expression of Fas Ligand (inducer of apoptosis), and
TRAIL (TNF-related apoptosis-inducing ligand)-mediated effector functions (37, 38). NK cells,
upon proper activation, can also provide help to dendritic cells during anti-tumor responses (39).
NK T cells recognize self- and foreign lipids and glycolipids in the context of CD 1 d molecules
on target cells, and rapidly secrete cytokines such as IL-4 and IFN- y (40). Macrophages
infiltrating the tumor bed can produce IL-12, which causes more IFN- y production by NK cells;
macrophages themselves, upon exposure to IFN- y, can also exert tumoricidal mechanisms (41,
42). The cells of the innate immunity, through cytokine secretion and non-specific killing of
tumor cells, facilitate release of tumor antigens from dead tumor cells and recruit tumor antigen-
specific effectors of the adaptive immunity, leading to the activation of antigen-specific T cells.
... ""... .  ... ....  ...............
Tumor cells
Figure 1-1: Schematic of an anti-tumor immune response. An ideal anti-tumor response is
initiated when cells of the innate immunity, such as NK cells and macrophages, liberate tumor
antigens. The tumor antigens can either drain to the lymph nodes themselves, or be picked up by
dendritic cells for transport to the regional lymph nodes, where antigen-specific T cells are activated.
The activated effector T cells then migrate to the tumor site and attack the tumor cells.
Ironically, however, these effectors in both innate and adaptive immune responses against
cancer in reality also have the potential of promoting tumor development. In the recently-refined
notion of immunosurveillance, called the immunoediting hypothesis, immunosurveillance
consists of the 'elimination' phase of an anti-tumor response (43). With the increased immune
pressure on the tumors, mutations occurring in the surviving tumor cells select for tumors
resistant to immune elimination. Tumor cells downregulate their antigen as well as MHC I
expressions (44), upregulate anti-apoptotic signals (45), and become insensitive to IFN- y (15).
In the 'equilibrium' phase that follows after any tumor variant survives the initial elimination
phase, lymphocytes are able to control tumor growth but not completely eliminate them. The
tumor cells that selectively survive the equilibrium phase then enter the 'escape' phase and
continue to grow, showing resistance to immune responses (43). It is usually in this escape
phase when tumors become clinically detectable. The immune system thus inadvertently takes
the dual task of generating a response that is supposed to be a beneficial, tumor-eliminating
response, and one that sculpts the tumors to become more aggressive and uncontrollable. Cancer
vaccines are thus being developed to overcome the growing and resistant tumor cells to push the
tumor-immune system dynamics back towards the elimination phase.
1.1.3 Existing cancer vaccines and those in development
With the recognition of the ability of the immune cells to fight against tumor cells, cancer
vaccines have been in development in hope to boost and support the immune responses against
tumors. Traditional vaccines that are already in clinical use are prophylactic, or preventive,
vaccines against viruses, bacteria, or fungi to prevent future infection, whereas cancer vaccines
can either be prophylactic or therapeutic (targeting to treat existing cancers). Despite the amount
of research in the development of cancer vaccines, only a few cancer vaccines have been
approved by the US Food and Drug Administration, including vaccines against hepatitis B
(which can lead to certain types of liver cancer) and human papillomavirus (HPV; which can
cause cervical cancer), which are both prophylactic against viruses that may cause cancer (46).
Therapeutic vaccines that are under investigation and in clinical trials can be divided into several
categories: 1) monoclonal antibodies; 2) peptide vaccines; 3) whole cell tumor vaccines; 4)
dendritic cell vaccines; 5) viral vectors and DNA vaccines; and 6) idiotype vaccines (46, 47).
Monoclonal antibody vaccines are passive immunotherapy strategies; monoclonal antibodies are
directed against surface markers that are over-expressed on tumor cells, which can keep the
tumor growth on hold. In peptide vaccines, peptides, or protein fragments of tumor antigens,
that are shared amongst the same type of cancer or isolated from patients, are directly injected
into patients along with adjuvants (substances that help stimulate the immune system to produce
a sufficient response to eliminate the target). Collections of tumor lines or tumor cells taken
from patients themselves can also be used as a whole cell tumor vaccine to present a mixture of
antigens that can potentially stimulate an immune response. Dendritic cell vaccines are
autologous cell vaccines that involve isolation of patients' dendritic cells from peripheral blood.
The dendritic cells are then expanded, matured, and loaded with tumor antigens ex vivo, after
which they are injected back into the patients in hope to activate the antigen-specific T cell
population. Tumor antigen proteins can also be generated using viral vectors and DNA to
transduce dendritic cells to express the tumor antigens. If generated successfully, the immune
response can be directed against dendritic cells expressing the onco-antigens and subsequently
attack the tumor cells. Idiotype vaccines target the B-cell receptor of B-cell malignancies as a
unique antigen, and recombinant forms of these receptor proteins can be injected into patients
like peptide vaccines.
Despite the many forms cancer vaccines take, the essential components of cancer vaccines
generally include the antigen that the specific target tumor expresses, and an adjuvant that
stimulates the immune system to produce a sufficient response to eliminate the target. The
antigen used should ideally be expressed only on the tumor cells and not on normal cells, and
should be carefully selected, depending on whether humoral or cellular immune responses are to
be induced (48). There are many adjuvants used in cancer as well as other types of vaccines,
including cytokines (49), dendritic cells (which are considered to be physiological adjuvants)
(50), alum (51), MPL (monophosphoryl lipid A) (52), and MF59(53).
Since efforts from individual scientists and researchers trying to find a cure for cancer using
monotherapies have generally been unsuccessful, cancer immunotherapy is now entering a new
era of combination therapies, combining different vaccine strategies as well as combining
immunotherapy with the traditional cancer therapy strategies like chemotherapies.
1.2 Challenges in Cancer Vaccines
Despite much of the effort that has gone into finding therapeutic vaccines for cancer, tumor
cells exert multiple mechanisms to survive anti-tumor immune responses and hamper the
generation of effective anti-tumor response. Tumor cells are derived from the host's own cells,
and they mostly express self-antigens that the host immune system is tolerant against, making the
tumor antigens very weakly immunogenic (54). Even when a successful immune response is
initiated in the host, the tumor cells evade (immune evasion) or locally suppress
(immunosuppression) the immune responses (47). Mechanisms of immune evasion by tumor
cells include stromal barrier formation and secretion of factors that prevent efficient DC
maturation and attainment of proper effector functions (55-57); tumors also establish a positive
pressure gradient to hinder lymphocyte infiltration into the tumors (47). Even when antigen-
specific effector cells are generated, the infiltration of these cells into the tumors has been limited
(58-61). In addition, tumor cells also actively suppress the immune responses via secretion of
factors, such as those that impair the functions and proper maturation of dendritic cells, causing
local accumulation of immature myeloid-derived suppressor cells (62). These myeloid
suppressor cells disable antigen recognition by CD8 T cells by nitration of TCR-CD8 T cell
receptor complex, inducing CD8 T cell anergy (63). Tumor cells also downregulate the
production of TNF-a and nitric oxide from macrophages inside the tumors, making the
macrophages less tumoricidal than the ones that participate in non-tumor related inflammatory
activities, while the tumors cause an increase in the level of nitric oxide, which is known to
suppress lymphocyte activity, distal to the tumor site, suppressing the anti-tumor effector
functions of circulating lymphocytes (64). Recruitment of regulatory T cells, cells that normally
regulate the extent of inflammation to prevent autoimmune diseases and overly activated
immune responses, to the tumor bed further inhibits anti-tumor immune responses (65, 66).
Both immune evasion, preventing therapeutic agents to circulate into the tumor core using the
tumor barrier, and immunosuppression by tumors play a large role in why effective cancer
vaccines have not been developed yet. Currentt attempts in finding an effective cancer vaccine
thus focus on countering immunosuppression from tumors, rescuing the dormant,
immunosuppressed effector cells.
1.3 'Vaccination Nodes': Motivation and Significance
1.3.1 Hypothesis
In order to address some of the challenges that have faced cancer immunotherapy, we have
hypothesized that by providing a synthetic microenvironment as a 'military base,' for both
exogenously injected and endogenously recruited effector cells right next to the tumor cells, but
possibly protected from multiple negative effects of the tumor itself, we would be able to mount
a vigorous response against cancer cells (Figure 1-2). Many of the current vaccine strategies
seek to promote the robust infiltration of tumors with functional immune cells to promote tumor
destruction. However, defects in tumor vasculature, suppressive signals produced by tumor cells
or co-opted tumor-resident immune cells, and rapid tumor growth can limit the ability of
activated and competent immune cells from accumulating. Peri-tumoral provision of an
inflammatory milieu using injectable hydrogels could potentially concentrate immune effector
functions at the tumor site and maintain a continuous infiltration of effectors, thus maintaining
the adaptive phases of anti-tumor responses, which usually fail to take place in many of the
immunotherapy strategies explored so far.
Furthermore, in addition to providing a scaffold for anti-tumor immune cells, we
hypothesized that the injectable matrix could also enable delivery of immunoregulatory factors
that can facilitate anti-tumor immune responses. Systemic administration of high dosages of
factors that have anti-tumor properties, such as Interleukin-2 (IL-2), are known to be toxic to
patients (49, 67). Thus, sustained release of immunocytokines and other immunomodulatory
factors from gels or microparticles at a tumor site has been explored and demonstrated to
enhance local immunotherapies by reducing systemic exposure to these potent factors and
provide more sustained local concentrations of these factors at the tumor site (49, 67-69). Local
application of certain combinations of cytokine, chemotherapy, and/or immunostimulatory
ligand treatments to treat established tumors has shown promise in not only eliminating treated
tumors but also generating systemic immunity capable of destroying large distal tumors (49, 69).
Thus, the use of biomaterials to deliver local combinatorial immunotherapies may lead to further
enhancements in the potency and safety of such treatments.
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Figure 1-2: Schematic of the concept of our 'vaccination node' hypothesis. Wehypothesized that by creating a synthetic immunoplatform that can attract a number of effector
cells equipped to fight against cancer cells to the injection site, we would be able to
concentrate and direct the effector functions against tumors at the tumor site. The hydrogel
material would act like a 'military platform' that the endogenous cells can use to mount a
response against the tumor cells.
Matrix-based immunotherapy moreover allows for examination of cells that traffic around
the tumors. Several studies have suggested that events that occur systemically and locally during
anti-tumor responses are not correlated (64, 70); for example, systemic generation of antigen-
specific T cells has not always resulted in the presence of the antigen-specific effector cells
inside the tumor microenvironment (58, 60, 61). The dissociation of systemic and local
responses against cancer indicates a necessity for understanding what exactly happens locally at
the tumor site. Tumor-infiltrating cells (TILs) have provided valuable insight into the prognosis
of cancer patient survival (29, 71-73). However, tumor-free survivors do not have any tumors to
be analyzed, and local anti-tumor mechanisms that have taken place in these patients cannot be
studied. Matrix-based immunization, therefore, allows for identification and analyses of cells
that are attracted to the peripheral site even for tumor-free survivors. The preliminary studies
conducted to select an injectable matrix material appropriate for our applications are shown in
Appendix A.
1.4 Outline of thesis work
The battle against cancer involves an intricate and often delicate balance between cancerous
cells evading and suppressing anti-tumor responses and immune cells, both specific and non-
specific for onco-antigens, attempting to control and eliminate the malignant, abnormally
growing cells. In this thesis work, we demonstrate that providing a scaffold, or a 'military base,'
for endogenous effector cells near tumor masses to mount a vigorous response against cancer
cells, and concentrating effector functions of the anti-tumor response at the tumor site, help tip
the balance in favor of the fighting effector immune cells in controlling tumor growths and
survival time of the mice. In Chapter 2, we show the development and characterization of
injectable self-gelling alginate hydrogels. Since alginate forms gels almost instantaneously from
the point of contact with soluble calcium ions, addition of calcium ions makes the gel difficult to
be injected using regular syringes. By way of providing an internal source of calcium uniformly
throughout the alginate matrix precursor solution, using 'calcium reservoir microspheres'
(CRMs), also synthesized with alginate, the alginate becomes injectable. In Chapter 3,
'vaccination nodes' consisting of self-gelling alginate encapsulating activated, mature bone-
marrow derived dendritic cells (BMDCs) are shown to mediate an antigen specific response and
re-traffic the effector T cells and dendritic cells to a desired peripheral injection site. The
phenomenon was a product of a synergistic effect between the activated dendritic cells and
alginate and not of dendritic cells alone. Studies using these vaccination nodes as an
immunotherapy against established tumors are shown in Chapter 4. We demonstrate that co-
delivery of IL-15 superagonist (receptor-cytokine complex) improves the tumor growth
inhibition effect and the survival length of the mice treated. Incorporation of IL-15 complex,
furthermore, obviated the need for ex-vivo expanded dendritic cells, and improvement of tumor
growth control and survival was achieved by giving a second immunization to the mice at the
tumor site. The injectable alginate hydrogel, in addition, not only allowed for a sustained release
of immunomodulatory factors and production of a local inflammatory milieu, but also let us
study the fingerprints of cells that traffic to the tumor/injection site that correlated well with the
success of the vaccination. Self-gelling alginate thus is a versatile matrix material that can be
used to deliver various immuno-factors and provides a robust tool for examining and modulating
the effect of these factors as well as the cell types that participate in the local anti-tumor
responses.
Chapter 2
Development and Characterization of
Self-Gelling Alginate
In this chapter, we describe the development and characterization of injectable alginate
formulations via self-gelation strategy. The injectable nature of the hydrogel renders the material
suitable for clinical applications and friendly to patients receiving potential cancer treatments
using the self-gelling alginate system.
2.1 Introduction
Alginate is a natural polysaccharide commonly obtained from brown seaweed, which forms
a physical hydrogel in the presence of divalent cations such as calcium. Due to its
biocompatibility, mildness of gelation conditions, and low immunogenicity, purified alginate has
been widely used in food and pharmaceutical industries, as well as for many biomedical,
biomaterial, and therapeutic applications (74-78). Alginate chains are multiblock copolymers
consisting of poly-D-mannuronic acid (M) blocks, poly-L-guluronic acid (G) blocks, and
alternating G/M blocks. The size, proportions, and the distribution of each block influence both
the physical and chemical properties of alginate, with G units contributing to the crosslinking
capacity through stereocomplexation in an "egg-box" conformation(79), while M and G/M
blocks provide flexibility to the resulting networks. Alginate is stable against breakdown by
mammalian enzymes but dissolves and can be eliminated through the kidneys in vivo;
alternatively, partial oxidation of uronic units of sodium alginate can be used to make alginate
susceptible to hydrolytic breakdown in vivo(80-82).
Because of the cooperative nature of crosslinking by G units and the small size of the
crosslinking ions, gelation of alginate can occur very rapidly. For example, aqueous alginate
solutions added dropwise into a calcium-containing aqueous bath form gel beads via rapid
diffusion of calcium into the alginate. Such 'external gelation' methods have been employed for
entrapment of cells or macromolecules into microbeads for therapeutic agent delivery (75, 76,
83). Alternatively, 'internal' gelation methods have been developed, in which the gelling ions
are supplied from within an initially soluble alginate solution. For example, calcium salts with
low water solubility, such as carbonate, sulfate, and phosphate (74, 84-87) can be mixed with
alginate precursor solutions; slow dissolution of these inorganic calcium sources controllably
crosslinks the surrounding alginate solution. Since many calcium salts and complexed ions show
pH-dependent solubility, molecules such as polyphosphate or ethylenediamine tetraacetic acid
(EDTA) (84, 88, 89) or chloride compounds such as ammonium chloride(88) may be added to
alginate solutions to promote gradual release of calcium by changing the pH of the release
medium.
To achieve non-invasive delivery of alginate gels for biomedical applications, variations on
the concept of internal gelation have been employed to create 'self-gelling' formulations of
alginate that facilitate injection of alginate followed by in situ crosslinking in vivo. Melvic et al
(90) lyophilized calcium alginate gels and milled these dried solids to form calcium alginate
particles, which were used as a source of slowly-released calcium ions when mixed with soluble
alginate solutions. Thermally triggered release of calcium from phospholipid vesicles mixed
with alginate solutions, employing liposomes that rupture at a physiological temperature, has
also been demonstrated as a method for in situ formation of alginate hydrogels (91).
Alternatively, for applications where soft gels are suitable, alginate with low levels of calcium
added can be formulated as a viscous solution that is still injectable (92).
In this chapter, we show characterization of the mechanical properties and structure of gels
formed from self-gelling alginate formulations, utilizing internal calcium source from calcium
reservoir alginate microspheres, in vitro and in vivo. Compositions were chosen such that the
gels form low-viscosity solutions amenable to mixing/drawing in a syringe, and set to fstable
gels following injection via crosslinks contributed by ions in the interstitial fluid in vivo. A
similar strategy of injecting low-viscosity calcium-crosslinked alginate (via homogenization and
dispersion of calcium gluconate in a sodium alginate solution) followed by gelation in situ has
also been successfully employed for repair of myocardial infarction in rats in a recent study by
Landa, et al(93). In addition, we explored strategies to enhance the function of these gels in
immunotherapy, via the co-delivery of the immunomodulatory factors interleukin-2 (IL-2) and
CpG oligonucleotides in the matrix. We thus demonstrate two different strategies for
incorporating factors into these injectable matrices, encapsulation within the bulk matrix (IL-2),
or electrostatic anchoring to the surfaces of embedded alginate microspheres (CpG oligos). By
variable combination of these strategies, a flexible platform for cell delivery and supporting
factors is obtained. This modular approach to augmenting an injectable, biocompatible gel that
supports cellular infiltration with slow release of cytokines or presentation of factors
immobilized within the matrix may be useful in a range of soft tissue regenerative medicine
applications, in addition to our particular interest in immunotherapy of cancer.
2.2 Materials and Methods
2.2.1 Materials
Sterile alginates Pronova SLM20 (MW 75,000 - 220,000 g/mol, >50% M units; endotoxin
level <25EU/g) and Pronova SLG20 (MW 75,000 - 220,000 g/mol, >60% G units; endotoxin
level <25EU/g) were purchased from Novamatrix (FMC Biopolymers, Sandvika, Norway). All
antibodies were purchased from BD Biosciences (San Jose, CA). 2, 2, 4-trimethylpentane
(isooctane, ChromAR grade, 99.5% purity) was obtained from Mallinckrodt Baker (Phillipsburg,
NJ). Poly-L-lysine hydrobromide (MW 30,000-70,000 g/mol), FITC-poly-L-lysine
hydrobromide (MW 30,000-70,000 g/mol), and 6-aminofluorescein were obtained from Sigma-
Aldrich (St. Louis, MO). Mag-fura-2 tetrapotassium salt, was purchased from Invitrogen
(Carlsbad, CA). CpG oligonucleotides with a phosphorothioate backbone (CpG 1826, sequence
5'-/5AmMC6/TCC ATGACGTTCCTGACGTT-3') and FITC-CpG (FITC-CpG 1826, sequence
5'-/5AmMC6/ TCC ATGACGTTCCTGACGTT/36-FAM/-3') were synthesized by Integrated
DNA Technologies (Coralville, IA). Recombinant murine IL-2 was purchased from Peprotech
Inc (Rocky Hill, NJ). Hilyte FluorTM 647 amine was purchased from Anaspec, Inc (San Jose,
CA), and Slide-A-Lyzer Dialysis Cassettes (7000MWCO) from Pierce Biotechnology (Rockford,
IL). All other chemicals were purchased from Sigma and used as received unless otherwise
stated.
2.2.2 Fluorescent labeling of alginate
SLM20 alginate (0.02g/mL) was mixed with 9 mM EDC (1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride) and 9 mM sulfo-NHS (N-hydroxysulfo
succinimide) in PBS at 200 C for 2 hrs. An equal volume of 6-aminofluorescein (4.5 mM in 70%
ethanol) or Hilyte Fluor 647 (0.32 mM in water) was added to the alginate solution containing
EDC/Sulfo-NHS and reacted at 200 C for 18 hrs while rotating. The resulting solution was then
dialyzed (7 KDa MWCO) against 1 L PBS at 40C for 3 days with 3-5 changes of the dialysis
bath. Labeled alginate solution was adjusted to a concentration of 0.01g/mL in PBS, sterile-
filtered and stored in the dark at 40 C until use.
2.2.3 Calcium reservoir microsphere synthesis and self-gelling alginate
Alginate microspheres were synthesized (see Appendix C. 1 for detailed protocol), with 1.5
mL sorbitan monooleate, 0.5 mL polyethylene glycol sorbitan monooleate, and 35 mL isooctane,
homogenized for 3 min using an UltraTurrax T25 homogenizer (IKA Works, Wilmington, NC)
at a speed of 8x1000/min. Pronova SLG20 solution (0.01 g/mL in PBS, 400 pL) was added and
homogenized for 3 min, followed by addition of 25 pL aq. CaCl2 (0.05 g/mL) with
homogenization for 4 min. The resulting particles were washed once with 30 mL isooctane and
3X with 1 mL of deionized, distilled (95) water, then resuspended in DD water for a final
volume of 1 mL and stored at 40C until use. Microsphere sizes were determined from optical
micrographs taken with a Zeiss Axiovert 200 epifluorescence microscope at 40X and analyzed
with MetaMorph software (Molecular Devices, Downingtown, PA). Endotoxin levels in the
microspheres were assessed using the QCL-1000® Endpoint Chromogenic LAL Assay (Lonza,
Basel, Switzerland) according to the manufacturer's instructions. This measurement on high-G
alginate microspheres yielded 0.000615EU/ug particles, well below levels stimulatory for innate
immune cells (96-98).
Self-gelling alginate gels were formulated by pelleting calcium reservoir SLG20
microspheres (quantities as noted in the text), resuspending the particles in a minimal residual
volume of water with a bath sonicator for 2 min, and adding Pronova SLM20 (0.01 g/mL in PBS)
alginate matrix to a constant final volume (i.e. 170 jtL microspheres+alginate), dispersing
microspheres throughout the solution. For delivery of self-gelling alginate in vivo, 150tL of
microspheres/solution mixture was immediately drawn by an insulin syringe (28gauge, BD
Biosciences) and injected s.c. in anesthetized mice.
2.2.4 Ca2+quantification in alginate microspheres and self-gelled alginate
Alginate microspheres (100 jLL of stock suspension) were pelleted and dissolved with EDTA
(ethylenediaminetetraacetic acid disodium salt dehydrate; 100 jiL, 2.5mM in water) and 890 gL
PBS, with 10 min of sonication. Mag-fura-2 dye (5 tg/mL) was added to the dissolved
microsphere solution and fluorescence was recorded on a SpectraMax M2 Microplate Reader
(Molecular Devices, Sunnyvale, CA) at 340ex/515em and 380ex/515em in a flat-bottom 96-well
UV-transparent plate (BD Falcon, Franklin Lakes, NJ) alongside a series of Ca2+ dilution
standards. Calcium levels were determined using the ratio of emission intensities recorded from
340 nm and 380 nm excitation, calibrated to calcium concentration by the standard dilutions and
accounting for the fraction of calcium chelated by EDTA. In parallel, some microsphere samples
were dissolved with EDTA and elemental analysis was performed using inductively coupled
plasma optical emission spectroscopy by Quantitative Technologies, Inc. (Whitehouse, NJ).
Elemental analysis on in vitro-formed or explanted gels was performed following digestion of
gels with 100 pL of 100 mM EDTA andl00 jtL of 10 mg/mL alginate lyase for 24 hrs at 200 C or
until dissolved.
2.2.5 Kinetics of Ca2+ redistribution in self-gelling formulations
For time-lapse microscopy analysis of Ca2+ redistribution from microspheres into alginate
solutions, 200 iL of alginate matrix solution (0.01 g/mL SLM20) pre-incubated with 25 pg/mL
mag-fura-2 solution for 2 hrs was imaged in a 8-well Labtek chambered coverslip (Nalge Nunc,
Rochester, NY) on a Zeiss Axiovert 200 epifluorescence microscope equipped with a CoolSnap
HQ CCD camera (Princeton Instruments Inc., Acton, MA). Time-lapse fluorescence images of
the samples were collected at 340 nm ex/515 nm em and 380 nm ex/515 nm em at 45 sec
intervals for 10 min using a 40x objective to establish the baseline fluorescence. Microspheres
(1.25x10 6) were then mixed with the matrix solution containing the dye and time-lapse recording
of mag-fura fluorescence was continued for 60 min. All data was acquired and fluorescence
emission ratios (340 ex:380 ex) were analyzed using Metamorph software.
Complementary Ca2+ redistribution measurements were made for bulk solutions using a
fluorescence plate reader: calcium reservoir microspheres were mixed with matrix alginate and at
staggered timepoints following mixing, microsphere/SLM20 solutions were centrifuged at
16000xg for 10 min to separate microspheres from the alginate solution. The supernatant
solution was mixed with mag-fura-2 dye (5 pg/mL) in a UV-transparent 96-well plate and
fluorescence signals were acquired using a SpectraMax M2 Microplate Reader and analyzed as
described above.
2.2.6 Shear modulus measurements
The shear moduli (G' and G") of self-gelled alginate gels were measured using a parallel
plate configuration on an AR-G2 rheometer (TA instruments, New Castle, DE) connected to a
Julabo F25 Refrigerated/Heating Circulator (Seelbach/Black Forest, Germany). Self-gelling
alginate containing different amounts of SLG20 microspheres were mixed and immediately
pipetted onto the bottom plate and were allowed to gel for 1 hr at 250 C. A solvent trap cover
was used to prevent water loss during gelation/measurements. Oscillatory shear was then
applied at an angular frequency of 1 rad/s and a controlled strain of 5% with 450gpm gap, a
condition that showed minimal wall slip effects. Time sweep measurements were taken for 35
min (the moduli reported are the time-averaged values), followed by frequency and strain sweeps
for each sample.
2.2.7 Animals and cells
Animals were cared for in the USDA-inspected MIT Animal Facility under federal, state,
local and NIH guidelines for animal care. C57B1/6 mice and C57B1/6 mice expressing green
fluorescent protein (GFP) under the chicken p-actin promoter and cytomegalovirus enhancer
were obtained from Jackson Laboratories. Bone marrow-derived dendritic cells (BMDCs) were
prepared by isolating bone marrow from the tibias and femurs of C57B1/6 mice or GFP + mice
and culturing them in vitro over 6 days in the presence of 10ng/mL GM-CSF in complete
medium (RPMI 1640 containing 10% FCS, 2 mM L-Glutamine, penicillin/streptomycin, and 50
ptM 2-mercaptoethanol) following a modification of the procedure of Inaba (99) as previously
reported (100). BMDCs were used on day 6 or 7 as resting immature DCs or stimulated with
CpG overnight (-18 hrs) as activated mature DCs.
2.2.8 IL-2 release from self-gelling alginate in vitro
Alginate particles (3x106) were pelleted as above, mixed with 2 ptg IL-2 (100pg/mL) for 18
hrs at 4°C, and then directly added to 1% Pronova SLM20 (140 ptL of 0.01g/mL in PBS) matrix
to form a gel. All samples were allowed to gel at 370 C for 2 hrs while gently shaking, followed
by a gentle wash with 1 mL of complete medium. Release studies were conducted by adding
lmL of the complete medium to gels at 370 C; 950 pL of supernatant was removed at each time
point over 7 days and fresh medium added to replace that withdrawn. The supernatants were
stored at 40C until all the time points were collected, and on day 7 the alginate gels were digested
with 10mg/mL alginate lyase for -20 min at 370C to recover all remaining cytokine. The
amounts of cytokine in supernatants from each sample were quantified by sandwich ELISA
according to the manufacturer's instructions (R&D Systems, Minneapolis, MN). The
bioactivity of IL-2 released from alginate was tested by measuring proliferation induced in the
IL-2-dependent cell line CTLL-2 (generously provided by Laboratory of Prof.Dane Wittrup at
MIT) compared to solution standards of IL-2, using the WST-1 proliferation assay (Roche
Applied Science, Mannheim, Germany) according to the manufacturer's instructions, with
10,000 CTLL-2 cells/well in a 96-well plate and 48-hour incubation before adding WST-1.
2.2.9 CpG/Poly-L-Lysine-coated alginate particles and BMDC stimulation
Alginate microspheres synthesized under sterile conditions were incubated with 2 mg/mL
poly-L-lysine in sterile DD H20 for 2 hr at 20 0C while rotating with a Labquake rotator, washed
3X with 1 mL of sterile DD H20, followed by incubation with 50 p.M CpG or FITC-CpG (in
PBS) solution (5 nmoles CpG/FITC-CpG per 106 particles) overnight at 40C while rotating. The
microspheres were washed 3X again with sterile DD H20 and resuspended at a concentration of
10x10 particles/mL.
Microspheres (106 or 0.5x10 6 unmodified, Poly-L-lysine coated, or CPG/PLL-coated) or
control soluble CpG were added to day-5 BMDC cultures containing 10 cells/mL and incubated
at 370C for 18 hrs. Treated or control BMDCs were harvested from culture plates, blocked with
10 p.g/mL anti-CD 16/CD32 antibody for 10 min at 40 C, and stained with fluorescent antibodies
against surface markers (CD11 c, I-A b, and CD40) for 20 min on ice. Stained cells were analyzed
on a BD FACSCalibur flow cytometer (BD Biosciences).
2.2.10 FITC-CpG release from FITC-CpG/PLL alginate microspheres
FITC-CpG/PLL-coated alginate microspheres were prepared as described above, and 106
particles were either aliquotted into Eppendorf tubes by themselves or encapsulated into self-
gelled alginate (140 [tL 0.01 g/mL SLM20 in PBS + 3x10 6 calcium reservoir microspheres)
containing 11 mM calcium. Samples were washed once with 1 mL of phenol-red free RPMI
1640 with 10% FCS. Release measurements were initiated by adding 300 .tL of complete
medium (phenol-red free); at each timepoint the supernatant was collected and 300 [tL fresh
medium added to the samples over a 7-day period. The amount of FITC-CpG released into the
media was quantified by the intensity of FITC fluorescence in the supernatant using a Perkin-
Elmer HTS 7000 Plus Bio Assay Reader (Waltham, MA) with 492 nm ex and 535 nm em,
calibrated by a serial dilution of FITC-CpG standard solutions.
2.2.11 Fluorescence and reflectance-mode confocal microscopy
For in vitro samples, SLM20 alginate labeled with 6-aminofluorescein (130gtL of 0.01 g/mL in
PBS) was mixed with 4x10 6 calcium reservoir microspheres (-14.8mM Ca2+). For injected gels,
C57B1/6 BMDCs (2x106) were washed 3X with PBS and mixed with 160 gtL fluorescently-
labeled SLM20 (0.01 g/mL in PBS) and 106 calcium-reservoir microspheres, then 150pL of the
alginate/cell suspension was injected s.c. into the flanks of anesthetized C57B1/6 or GFP + mice
with a 28 gauge insulin syringe (BD Biosciences). Animals were euthanized and gels were
explanted from mice 22-48 hrs after inoculation and imaged using a Zeiss LSM 510 confocal
microscope (Thornwood, NY). Reflectance mode imaging was obtained by collecting back-
scattered light using a 488nm laser for illumination. 3D reconstructed images were obtained
through 100-300 [tm depths in 1-2 gtm z-steps using a 40x water-immersion objective. 3D
reconstruction and projections over multiple z-planes were processed using Volocity software
(Improvision Inc, Waltham, MA).
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Figure 2-1: Schematic of self-gelling alginate formulations based on calcium reservoir alginate
microspheres. Calcium-crosslinked alginate microspheres and microspheres modified with CpG
oligonucleotides are mixed with soluble 'matrix' alginate in PBS containing soluble IL-2 (which may also
contain cells or other factors). Diffusion of calcium ions in the microspheres into the surrounding solution
induces crosslinking of the soluble alginate and gel formation. The inset figure outlines the process of
calcium reservoir alginate microsphere synthesis via a water-in-oil emulsion of alginate in isooctane in the
presence of surfactants. The micrograph shows the brightfield optical micrograph of as-synthesized
calcium-crosslinked alginate microspheres (scale bar:50 pm).
2.3 Results and Discussion
2.3.1 Characterization ofcalcium-reservoir microspheres
Prior studies have demonstrated that alginate microspheres of sizes 1-250 gm diameter can be
prepared using water-in-oil emulsions (101, 102). Similarly, we synthesized calcium-loaded
alginate microspheres by emulsification of an aq. solution of alginate in isooctane containing
surfactants, followed by crosslinking of alginate droplets via addition of aqueous calcium to the
emulsion (Figure 2-1). In order to form microsphere reservoirs that could bind substantial
amounts of calcium, particles were formed from high-G alginate (Pronova SLG20, >60% G unit),
based on the higher affinity of G units of alginate for calcium compared to M units (79, 103,
104). Each synthesis produced -10x10 6 calcium reservoir microspheres (CRMs) and the
resulting microspheres had mean diameters of 12 gm + 9 jtm with a pellet volume of -10 iL per
106 microspheres. Calcium loading was measured by dissolving the microspheres with EDTA
and PBS, followed by measurement of released ions using the calcium-sensitive fluorescent dye
mag-fura-2 (105-107). Using this technique, the microspheres were found to contain an average
of 1.5 ± 0.2 tmol of Ca2+ per mg alginate (n > 10 independent batches of particles). Elemental
analysis of these samples yielded an average of 1.6 ± 0.2 pmoles of Ca2 + (n=6), consistent with
the fluorescence assay. The microspheres exhibited no swelling over the course of a week and
were stable for at least 7 days in water. Analysis of the supernatant from CRM suspensions
using mag-fura-2 indicated that the concentration of free Ca2 + in the supernatant was effectively
zero and little Ca2+ was released into the aqueous phase during storage.
2.3.2 Gelation of alginate solutions using calcium-reservoir microspheres
The concept of self-gelling alginate using calcium-loaded microspheres is illustrated in Figure
2-1. Upon mixing of alginate microspheres with an alginate aqueous solution in PBS, calcium
ions rapidly diffused from the microspheres into the solution to form a stable alginate gel,
facilitated by sodium ion exchange. Alginate with a high M content (Pronova SLM20, >50% M
units), which forms a mechanically less rigid gel than G-rich alginate (84, 103, 108), was used as
the solution matrix component to favor cell infiltration into gels in their ultimate in vivo
application. To measure the kinetics of calcium redistribution upon mixing CRMs with matrix
alginate for self-gelation, we used the same microsphere/matrix composition applied for in vivo
injections described later (9x10 5 CRMs mixed with 150pL SLM20 alginate (0.01 g/mL in PBS)).
As described below, this composition does not form a stable gel in vitro but forms a low-
viscosity alginate solution (additional calcium from the surrounding tissues contributes in vivo);
we used this sub-gelation condition as a strategy to allow calcium redistribution followed by
rapid separation of microspheres from the still-fluid alginate matrix solution (via centrifugation),
in order to measure the amount of calcium released into the matrix solution. First, calcium
redistribution kinetics was characterized using a calcium-sensitive dye, mag-fura-2, tracking the
ratio of fluorescence emission following excitation at wavelengths of 340 nm vs. 380 nm over
time by time-lapse fluorescence microscopy. Figure 2-2A shows a representative temporal trace
of calcium levels detected in the alginate solution by mag-fura-2 following addition of CRMs,
illustrating the extremely rapid release of calcium into the PBS/alginate matrix. Taking into
account the physical act of mixing (-3 min), the microspheres released Ca2+ within the first
several min of mixing of the particles with the matrix solution. Bulk fluorescence measurements
on a fluorescent plate reader following separation of microspheres from the matrix alginate after
12 min showed 2.3-2.6 mM Ca 2+ in the alginate solution (data not shown), consistent with the
data from time-lapse microscopy, a concentration that was constant for up to 1 week. Since the
total calcium concentration in the alginate matrix + microspheres (as determined by elemental
analysis) was 3.7+0.3 mM for this composition, approximately 70% of calcium initially present
in the CRMs was released within the first few minutes, and the remaining calcium remained
sequestered within the particles for at least 7 days. Consistent with the rapid ion redistribution
kinetics measured by the calcium-sensitive dye reporter, when fluorescent polystyrene
nanoparticles (500 nm diam.) were mixed with self-gelling alginate containing a greater total
content of calcium by adding 4-fold more CRMs to alginate matrix solutions (14.8 mM total
calcium), time-lapse fluorescence imaging showed a cessation of nanoparticle Brownian motion
within 5 min, indicating gelation on short timescales when sufficient calcium-reservoir
microspheres were present (data not shown). This data is also consistent with a prior study,
which reported an increase of the shear elastic modulus of alginate within the first several
minutes of mixing of alginate with alginate-associated calcium (90).
The microscale structure of self-gelled alginate was visualized by employing fluorescein-
labeled SLM20 as the matrix mixed with unlabeled SLG20 microspheres (net calcium
concentration -14.8 mM). Examination of the structures of the resulting gels by confocal
microscopy showed a random distribution of the polydisperse calcium-reservoir microspheres
(indicated by the non-fluorescent spherical voids) throughout the alginate matrix (Figure 2-2B).
A B
Ca2+-loaded
microspheres added
" 3.5-
3.0 - I T T
.5-
E 1.0
-a. 0.5
0 10 20 30 40 50 60 70
time [min]
Figure 2-2: Calcium ions are rapidly released from calcium reservoir microspheres into the matrix
alginate. (A) Temporal trace of calcium concentration in 'matrix' alginate determined by fluorescence
microscopy using the calcium-sensitive dye mag-fura-2. Calcium reservoir microspheres (1.25x106) were
mixed with 200 pL SLM20 alginate in PBS (composition used for injection in vivo) and immediately imaged in
time-lapse microscopy. (Error bars = SD, every 10th timepoint). (B) 3D reconstruction of a self-gelling
alginate formulation containing 4x106 calcium reservoir microspheres in 130pL SLM20 matrix (14.8 mM Ca2+
overall), showing alginate microspheres (nonfluorescent voids) distributed throughout the fluorescent matrix.(scale bar: 50pm).
2.3.3 Mechanical properties of self-gelled alginate hydrogels
Because the concentration of CRMs directly determines the amount of calcium in self-gelling
formulation, the mechanical properties of the resulting gels were directly modulated by the
amounts of particles added. Figure 2-3A shows the shear moduli of self-gelled alginate
containing different amounts of SLG20 microspheres, as measured by parallel plate rheometer.
Each gel composition was allowed to set on the rheometer plate for 1 hr at 250 C before small
oscillatory shear was applied. Figure 2-3B shows the shear modulus over a range of angular
frequencies for gels with -8.6mM calcium concentration, showing the dominance of elastic
behavior over two decades of angular frequency. Similar behavior was seen for gels with
calcium concentrations above -6mM (data not shown). The amplitude of the strain (5%) used
for all the measurements fell within the linear region of the viscoelastic spectrum as shown in
Figure 2-3C (for the case of -8.6mM calcium concentration). Prior studies have generally
reported elastic moduli measured for gels containing substantially higher calcium concentrations
(> 50-100 mM) and are on the order of 103 Pa (109-112). However, direct comparison is
difficult since the mechanical properties of alginate are affected by the alginate block structure,
molecular weight, G/M ratio, and concentration. The mechanical properties are also dependent
on the electrolyte composition of the gelling medium, since monovalent ions will compete for
binding sites despite the high affinity of calcium ions with alginate G units(l 13). Such a
mechanism is clearly involved in the present case where the matrix alginate was in PBS solution
(0.14M NaCl, 3mM KC1, 10mM K2HPO 4, pH=7.4), leading to mechanically soft gels as
observed by LeRoux et al. for alginate gelled in the presence of 0.15M NaCl (114), and as
Khromova observed for alginate gelled in the presence of KCl (88).
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Figure 2-3: Mechanical properties of self-gelling alginate gels are controlled by the amount of
calcium reservoir microspheres in the formulation. (A) Shear storage (G' (0)) and loss (G" (0))
moduli of self-gelled alginate containing different amounts of SLG20 microspheres were measured byparallel plate rheometer, showing an increase in the elastic shear moduli with the number of calcium
reservoir alginate microspheres for a fixed total volume of the final gels. (B) Frequency sweep of self-gelling alginate gel with 8.6mM total calcium content shows the elastic component of the modulus G' (*)dominating the mechanical behavior of the gel over the viscous component G" (0) over two decades of
angular frequency. (C) The magnitude of strain (5%) applied to the modulus measurement in fig 3A was
in the linear region of the viscoelastic spectrum. The plot shown is for the case of 8.6mM Ca2+ in a self-gelling alginate formulation ((G' (0)) and loss (G" (0)).
Ionically crosslinked alginate is easily displaced from equilibrium by mechanical forces, and
its behavior is heavily influenced by kinetics despite its elastic behavior at low strains (113). In
addition, alginate is a shear-thinning fluid (103). Thus, even for matrix/microsphere mixtures
providing > 6 mM total Ca2+, gels with constant and stable shear moduli were not achievable
when shear was applied immediately after loading onto the rheometer stage (data not shown);
precluding measurement of the change in shear modulus with time. However, this behavior
facilitated mixing of the matrix solution and microspheres; despite rapid ion release, uniform
mixing of the calcium-loaded microspheres and the matrix was feasible even at relatively high
CRM concentrations because application of shear during mixing disrupted crosslinking. The
self-gelling system is thus suitable for applications in which mechanically soft yet uniform and
stable gels are desired.
2.3.4 Sustained release of IL-2 from self-gelling alginate
Due to its mild gelation conditions, alginate has become an attractive candidate for
encapsulation and delivery of proteins and other drugs in recent years (94, 115-118). We are
particularly interested in the application of self-gelling alginate for co-delivery of immune cells
and immunoregulatory factors at tumor sites to promote anti-tumor immune responses. We
previously demonstrated that dendritic cells (DCs) are readily encapsulated in subcutaneously-
injected self-gelling alginate (94), and in order to augment their functions, we sought to co-
deliver immunoregulatory factors in these gels that could play complementary roles in
supporting anti-tumor immune responses: the immunocytokine interleukin-2 (IL-2) and CpG
oligonucleotides. To build on the self-gelling system already described, we encapsulated IL-2
into the gels, and used alginate microspheres as modular components to immobilize CpG on their
surfaces and mix them along with CRMs into matrix alginate solutions (Figure 2-1).
IL-2 is a cytokine that supports proliferation and effector functions of lymphocytes(1 19-123).
It is FDA-approved for treatment of metastatic melanoma and renal cell carcinoma via systemic
injection, but is known to have dose-limiting toxicity. Thus, strategies for local delivery at tumor
sites have been sought to maximize the effectiveness of this cytokine: Slow release of IL-2 has
been previously demonstrated using controlled release polymers (67, 124, 125), including
alginate (126). For IL-2 delivery in this self-gelling system, we mixed 2 jtg of murine IL-2 with
CRMs and matrix alginate solution for gelation (3x10 6 microspheres/140iL alginate matrix
solution, giving -I lmM Ca2+). Release of IL-2 from the resulting gels was measured by ELISA
analysis of gel supernatants over 7 days. As shown in Figure 2-4, the self-gelling alginate
released IL-2 in a sustained manner over a week in vitro, suggesting that cytokines can be co-
delivered from these gels into the surrounding microenvironment for a prolonged period
following injection. The bioactivity of IL-2 released from these gels (assessed using the IL-2-
dependent cell line CTLL-2) was statistically indistinguishable (95% bioactive) from control IL-
2 solutions (data not shown). We have previously shown that highly cationic proteins exhibit
very slow release from alginate gels due to electrostatic interactions with the matrix(127), but IL-
2 has an isoelectric point near neutral pH. Thus, similar to the conclusions of other studies of
cytokine release from alginate-based gels (126, 128),, we speculate that the release kinetics are
mediated primarily via diffusion of IL-2 through the molecular mesh of the alginate gel.
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Figure 2-5: CpG
oligonucleotide immobilization
on alginate microspheres and
activation of DCs by CpG-
bearing microspheres. (A)
Brightfield and fluorescence
(FITC) micrographs of calcium
reservoir microspheres coated
with polylysine and FITC-CpG.
(scale bars: 50pm). (B) Kinetics
of FITC-CpG release from
CpG/PLL/alginate particle
suspensions (5 nmol FITC-
CpG/106 microspheres) into
serum-containing cell culture
medium (0), CpG released from
self-gelled alginate (11.1mM
Ca 2+) containing the same
number of CpG/PLL/alginate
particles (0), or soluble CpG
released from self-gelled alginate
(11.1mM Ca2+) encapsulating
equivalent amounts of soluble
CpG (0). (C) 1x106 bone
marrow-derived dendritic cells
(BMDCs) were incubated with 5-
10x10 5 alginate microspheres,
PLL/alginate microspheres,
CpG/PLL/alginate microspheres,
or 1 pM soluble CpG (positive
control), or were left untreated
for 18 hrs, then analyzed for
surface marker expression by
flow cytometry. Shown are flow
cytometry scatter plots of
BMDCs gated on CD1 1c cells,
showing CD40 and MHC class II
expression. Heavy boxes
highlight highly mature
(activated) CD40hiMHC IIh i cells.
CpG/PLL-coated microspheres
were also able to trigger IL-6 (D)
and IL-12p70 (E) secretions in
BMDCs at least as efficiently as
the soluble CpG did.
2.3.5 Functionalization of alginate microspheres with CpG oligonucleotides
In addition to providing IL-2 locally to recruited T-cells, we sought a strategy to provide
activation signals locally to host DCs attracted to injectable alginate gels. CpG oligonucleotides,
short single-stranded DNA oligos that mimic bacterial DNA strands and activate dendritic cells
via Toll-like receptor-9, have been shown to potently activate DCs in cancer settings and to
break tolerance to tumor antigens (129-133). Thus, we tested an approach to immobilize CpG
oligos electrostatically on the surface of alginate microspheres for incorporation into self-gelling
alginate formulations (Figure 2-1): the polycation poly-L-lysine (PLL) was adsorbed to the
anionic surfaces of CRMs followed by electrostatic adsorption of CpG oligos (unlabeled or
FITC-tagged CpG) to the PLL-modified alginate particles. Fluorescence micrographs of FITC-
CpG/PLL/alginate particles (Figure 2-5A) showed clear binding of FITC-CpG to PLL-modified
microspheres, and fluorescence measurements showed that -88% of the FITC-CpG added (5
nmol FITC-CpG incubated with 106 particles) bound to PLL-coated microspheres. To assess the
stability of CpG binding to PLL/alginate particles, we measured the release of fluorescent CpG
into supernatants of CpG/PLL/alginate particle suspensions, self-gelled alginate containing the
same number of CpG/PLL/alginate particles, or self-gelled alginate encapsulating equivalent
amounts of soluble CpG (not immobilized). As shown in Figure 2-5B, most soluble FITC-CpG
was released from self-gelling alginate by -5 days, whereas release of CpG bound to particles
was substantially slower, with only -20% released over 1 week from either the particles alone or
from the particles encapsulated in self-gelling alginate.
In order to test whether CpG bound to alginate particles was capable of eliciting DC
activation, bone-marrow derived dendritic cells (BMDCs) were incubated with
CpG/PLL/alginate particles, PLL/alginate particles, alginate particles, or soluble CpG as a
positive control for 18 hrs. Figure 2-5C shows flow cytometry scatter plots gated on CD 11c +
cells for each condition: While almost no untreated control BMDCs have a highly mature
(activated) MHC IIhiCD40 hi phenotype, -20% of soluble CpG-stimulated DCs show this
phenotype by 18 hrs. BMDCs co-cultured with alginate or PLL/alginate microspheres showed
similar phenotypes as untreated immature DCs, whereas the CpG-coated particles caused
upregulation of the CD40 and MHC class II molecules on the DCs comparable to the soluble
CpG positive control. The viability of the cells, as assessed by PI (propidium iodide) staining,
did not differ among the conditions tested, indicating no cytotoxicity of the unmodified, PLL-
coated, or CpG/PLL-coated alginate microspheres (data not shown). In addition to upregulation
of these molecules involved in T-cell priming, another key function of activated DCs is the
production of proinflammatory cytokines. Figures 2-5D and E show that the CpG/PLL-coated
microspheres triggered secretion of the pro-inflammatory cytokines IL-6 and IL-12p70 by
BMDCs at least as efficiently as soluble CpG. Taken together, the above data suggests that
alginate microspheres do not themselves activate dendritic cells, consistent with published data
(134), but CpG oligonucleotides can be immobilized to these particles with slow release over
periods in excess of 1 week, and CpG-modified CRMs mediate potent activation of DCs.
Figure 2-6: Self-gelling alginate structures and
Sself-gelling alginate encapsulating Cy5-
CpGIPLL-coated alginate microspheres in
B ,vivo. (A) Brightfield (left) and reflectance mode
(right) images of self-gelling alginate (-9x105
microspheres in 150pL SLM20, O.Olg/mL) injected
subcutaneously into back flanks of mice and
explanted after 19 hrs shows micron-scale fibrils.
(scale bars: 50pm). (B) Brightfield (left) and
fluorescence confocal (right) images of self-gelling
alginate with 6-aminofluorescein-labeled SLM20
reveals the fibrillar structures are not associated
with alginate, indicating alginate forms
macroporous gels when injected subcutaneously
in vivo. (scale bars: 20pm). (C) Fluorescent Cy5-
CpG (purple) on the surfaces of PLL-modified
alginate microspheres was encapsulated into self-
gelling alginate and injected into GFP+ mice.
Cy5-CpG-coated microspheres are intact 48 hrs
post-injection (left, scale bar:25 pm) and are
accessible to infiltrating cells (right, shown in
green, scale bar:15 pm) that can ingest the
oligonucleotides. The micrographs are projections
of z-planes over 6 pm.
2.3.6 Gel structure and cellular infiltration of self-gelling alginate in vivo
In order to formulate a composition of CRMs and alginate matrix suitable for injection in vivo,
a series of compositions were tested for their ability to be readily drawn into and ejected from an
insulin syringe (28 gauge). Based on this practical requirement, a composition with 6x10 3
CRMs/ gL SLM20 solution was selected for testing in vivo (overall calcium concentration of
3.7+0.3 mM). Though the amount of crosslinking ions provided by the CRMs in this
formulation gives weak mechanical properties in vitro (Figure 2-3), we hypothesized that
calcium available in the interstitial fluid would contribute to crosslinking in vivo. Indeed, as
shown in Table 2-1, when this formulation was injected in vivo subcutaneously in C57B1/6 mice
and explanted after 2 hrs, -8 mM Ca2 + was detected in the recovered gels by elemental analysis,
corresponding to gels with elastic behavior over a range of oscillatory frequencies (Figures 2-3A
and B), and a Ca 2+ contribution from the interstitial fluid of -4.5 mM. When alginate precursor
solution was injected without added CRMs and explanted after 2 hrs, 5.5 mM calcium was
detected by elemental analysis, corresponding to gels with -60-fold lower shear moduli. Thus,
formulations with low concentrations of CRMs that are unable to themselves form stable gels
facilitate preparation of solutions/handling, while achieving soft but stable gels following
injection in vivo via the contribution of extracellular calcium in the tissue.
Table 2-1: Concentration of calcium ions in self-gelling alginate injected in vivo with or
without calcium reservoir microspheres
Microsphere- Total Ca 2' in Calculated Ca 2* contribution
Gel composition derived Ca2+ [mM] explanted gels [mM] from interstitial fluid [mM]
no microspheres 0 5.5-0.5 5 5-0.5
with microspheres 3.7--0.3 8.11 1.3 4.5±0.2
Gels formed in vitro in the studies described in previous sections form under idealized
conditions of pure buffer solutions, in the absence of serum or blood factors that are present in
vivo. To determine the structure of gels formed following in vivo injection, we injected self-
gelling alginate (6x10 3 CRMs/iL SLM20 solution) s.c. in C57B1/6 mice, explanted the resulting
gels 22-48 hrs after injection, and examined them in their native, hydrated state by 3D confocal
microscopy. We first examined the explanted gels by reflectance-mode confocal microscopy, a
technique to visualize the surface and volume architecture and topology of three-dimensional
matrices including natural biopolymers such as collagen (135, 136) as well as synthetic polymer
matrices (137). Nano-scale fibrils of extracellular matrix (ECM) can be resolved in situ through
this method without the need for exogenous labeling (136). Figure 2-6A shows representative
brightfield and reflectance-mode images of a self-gelled alginate matrix explanted 19 hrs after
injection, showing fibrillar structures that are of micron scale. Such fibrillar structures were
readily resolved within explanted alginate gels up to z-depths as far as reflectance could resolve
(-100 pm). In contrast, self-gelled alginate matrices formed in vitro were generally featureless
in reflectance microscopy (data not shown). To determine whether these fibrillar structures
represented a morphological change induced by alginate itself in vivo or were instead exogenous
like ECM components or blood factors such as fibrin depositing in the gels, fluorescent alginate
was injected, and we examined the structure in regions where fibrillar structures were prominent
enough to be observed directly in brightfield images. Figure 2-6B illustrates that fibrillar
structures formed within these gels (observed in brightfield) were not associated with alginate
chains (green fluorescence) but actually occupied voidspaces in the gels where alginate was
absent, demonstrating that the self-gelling alginate forms a macroporous structure in vivo,
possibly intertwined with as yet-undefined ECM components present in the serum, the interstitial
fluid, and/or the blood.
To determine whether CpG-coated microspheres could maintain local depots of CpG within
these gels in vivo, we injected self-gelling alginate carrying Cy5-labeled-CpG/PLL-coated
alginate microspheres, non-coated CRMs, and activated, unlabeled BMDCs into transgenic GFP+
mice. Gels were explanted after 24 or 48 hrs and analyzed by 3D confocal microscopy. Figure
2-6C shows that the Cy5-CpG-coated microspheres remained intact for at least 48 hrs in vivo
(left panel). Host cells (83) were also observed clustering around CpG-bearing microspheres
(Figure 2-6C right panel), and ingesting fluorescent CpG (Figure 2-6C left and right panels). We
have previously shown that a large number of host DCs infiltrate alginate gels loaded with
exogenous (syngeneic) activated DCs, within 48 hrs post injection (94). Availability of CpG on
the surface of alginate microspheres for a prolonged time period might thus enable sustained
local activation of recruited host DCs within the matrix.
Figure 2-7: Host cells Infiltrate self-gelling alginate and preferentially occupy void spaces
in the porous matrix. Fluorescence confocal microscope images of fluorescently labeled self-
gelling alginate (purple) explanted from back flanks of mice 48 hrs after injection. Infiltrating
GFP cells occupied void spaces in the macroporous gel structure and extended lamellipodia
into void spaces (blue arrows), with some phagocytic cells having ingested the matrix alginate
indicated by intracellular deposits of labeled alginate (white arrows). (scale bars: 50pm).
The success of a synthetic tissue engineering scaffold as a replacement for the native tissue
environment depends, among other factors, on its three-dimensional micro-architecture and
mechanical integrity, and ability to support cellular migration/infiltration (104, 138). In order to
visualize how host cells invade injected alginate matricesself-gelling alginate labeled with a far-
red dye, Hilyte Fluor 647, and containing activated, unlabeled BMDCs was injected into
transgenic GFP + mice. Fluorescence confocal microscopy of explanted gels at 48 hrs revealed
that host cells from the surrounding tissue invade the matrix via potentially two means (Figure 2-
7): cells occupied void spaces in the macroporous gel structure and extended lamellipodia into
void spaces (blue arrows), suggesting they preferentially infiltrated pre-existing pores. In
addition, phagocytic cells were also observed with intracellular deposits of alginate (clearly
intracellular when observed in reconstructed z-sections, not shown), indicating ingestion of
alginate by some cells as they infiltrated and made their own way through the matrix.
Examination of cell migration inside the gels under time-lapse microscopy also revealed smaller
cells rapidly migrating by squeezing through small void spaces. This observation is consistent
with the recent studies demonstrating that leukocytes can rapidly migrate through porous
matrices in the total absence of functional integrins (139). Thus, cellular infiltration is supported
by the macroporosity of in situ-gelled alginate, and potentially by ECM molecules deposited
within the gel during injection.
2.4 Summary
We analyzed the physical properties of self-gelling formulations of alginate formed by mixing
calcium reservoir alginate microspheres with a soluble alginate solution. We found that
relatively stable gels were formed for matrices loaded with >-6 mM Ca2+, whether provided by
microspheres only in vitro, or by a combination of ions from the reservoir microspheres and
surrounding tissue fluid in vivo. Redistribution of calcium ions from the reservoir microspheres
was rapid, reaching equilibrium within minutes of mixing with alginate aqueous solutions.
Cellular infiltration of these gels is supported by the macroporous morphology of gels formed in
situ following injection. This alginate microsphere + alginate solution strategy for forming gels
allows injectable formulations to be achieved without introducing additional compounds or
components to the system (the final matrix contains only alginate). In addition, the microspheres
can serve a dual function as both reservoirs for calcium and as microdepots for presentation or
release of co-factors in the matrix. The ability to incorporate soluble factors like IL-2 directly
into matrix and to use microspheres as modular components for augmenting these gels with
slowly released factors, such as CpG oligonucleotides as demonstrated here, may provide a
potent platform for immunotherapy when combined with delivery of immune cells. In addition,
such non-invasively delivered gels may be of general interest for tissue engineering and
regenerative medicine applications.
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Chapter 3
Mechanisms Behind Immune Responses
Elicited By Vaccination Nodes
Using the self-gelling alginate strategy as outlined in the previous chapter, in this part of the
thesis work we tested the concept of delivering DCs in an injectable hydrogel matrix, with the
aim of harboring dendritic cells for prolonged time periods at a defined site and
trapping/concentrating factors secreted by DCs to establish an inflammatory milieu in situ. The
creation of such inflammatory microenvironment successfully allowed for recruitment of key
immune effector cells that could potentially fight against cancerous cells near the injection site.
In this chapter, we also show how these pro-inflammatory vaccination nodes could mediate
antigen-specific immune responses and re-traffic the activated effector cells to a desired local
site.
3.1 Introduction
Dendritic cells (DCs) are potent initiators of immune responses, acting at the interface of the
innate and adaptive immune systems to activate a multitude of immune effector cells against
specific antigens. They are the key antigen presenting cells (APCs) involved in priming na've T
cells during primary immune responses (140, 141). Because of their critical role in initiating
immune responses, treatments based on the injection of autologous dendritic cells have become
an intensively investigated vaccination strategy in preclinical and clinical studies, particularly for
cancer immunotherapy (142-145). In dendritic cell vaccines for cancer, DCs derived from
peripheral blood cells are loaded with tumor antigens ex vivo and injected in patients to promote
anti-tumor T cell responses. In most studies, DCs have been injected at peripheral tissue sites
(e.g., subcutaneous or intradermal sites), with the expectation that the injected cells would
respond to normal homing cues and migrate to local draining lymph nodes. Upon reaching the
lymph nodes where na've T cells are concentrated, DCs can prime CD8+ tumor-specific T cells
that subsequently seek out and destroy tumors located elsewhere in the body. Promising data in
animal models has been obtained by this approach, but results from clinical trials have been
modest: even in cases where tumor specific CD8 + T effector cells have been successfully
generated, clinical responses have not always resulted (146-148). A limitation of such DC
vaccines, and many cancer vaccines in general, is that antigen-bearing DCs in lymphoid organs
have a limited ability to support the effector phase of the immune response following T cell
priming, which will be carried out primarily by activated T cells that leave the lymph nodes and
migrate to sites of antigen deposition in the peripheral tissues (e.g., infection sites or tumors).
This is particularly problematic in the case of anti-tumor immune responses, because tumor cells
themselves exert a number of mechanisms to locally suppress the effector functions of primed T
cells (63, 65, 149, 150). In addition, in many human cancers and animal models of cancer,
activated T cells fail to properly home to tumors to carry out their effector functions (71, 73, 151,
152). Thus, even a vaccine that successfully primes potent anti-tumor T cells in the secondary
lymphoid organs may not achieve the ultimate goal of destroying the tumor (54, 153).
To address these concerns, other studies have examined the injection of antigen-loaded
dendritic cells directly into tumors (154-156). Directly delivering DCs to the site of a
tumor/infection could improve immune responses by enabling DCs to prime anti-tumor T cells
locally at the site where they are needed, providing the injected DCs with direct access to
additional antigens, promoting attraction of additional T cells to the site through chemokine
production, and allowing DC inflammatory cytokine secretion to influence the local
microenvironment (157, 158). However, in the case of tumor immunotherapy, direct
intratumoral or peritumoral injection of DCs inhibits tumor growth but has limited ability to cure
mice of established tumors (154, 156, 159).
Although DCs delivered to tumors (or infection sites) might be well-positioned to both prime
anti-tumor T cells and support the effector phase of adaptive immune responses, the known short
lifespan of activated DCs (a few days) may limit the degree of success obtainable with this
approach. If host dendritic cells are not recruited to the site by the initial DC injection to
continue the process of antigen acquisition, T cell priming, and cytokine/chemokine production
started by the vaccination, the immune response may be shut off too early or returned to a
suppressed state prior to therapeutic benefit (i.e. tumor regression or infection resolution).
Because activated DCs secrete chemokines and cytokines that can attract and activate other DCs
(160-162), host dendritic cell recruitment following vaccination with exogenous DCs should in
principle be possible. As explained briefly in Chapter 1, we hypothesized that tissue-localized
recruitment of host dendritic cells and T cells to target tissue sites could be achieved if vaccine
DCs were delivered in a supporting matrix chosen to (1) provide space for cellular
infiltration/recruitment and to (163) promote local concentration of DC-derived chemokines and
cytokines, through binding to the matrix. Here we tested this hypothesis in a murine model,
utilizing a self-gelling formulation of alginate carrying dendritic cells, as described and
characterized in Chapter 2. The injectable matrix was obtained by mixing calcium-crosslinked
alginate microspheres with soluble alginate and dendritic cells, a formulation that gelled in a
matter of minutes to obtain stable, cell-infiltratable gels that persisted several weeks in vivo.
Using this system, we explored the concept of dendritic cell delivery in alginate gels in healthy
mice, and analyzed the host response to these gels in the steady state or in response to
immunization with specific antigen. In this approach, activated, antigen-loaded DCs were
injected at a subcutaneous site in the in situ-gelling hydrogel matrix. We found that these
injected DCs and alginate recruited endogenous host DCs and immune cells to the site, while
simultaneously a small number of the injected cells migrated to local lymph nodes (Figure 3-1).
T cells activated by these migrating DCs in the local draining lymph nodes were attracted back to
the alginate matrix in response to the local inflammatory milieu established in the gel. In this
way, a single injection provided antigen presenting cells to initiate naive T cell priming in the
native lymph nodes and simultaneously established a microenvironment drawing the activated T
cells to the site of injection, supported by host DCs that had infiltrated the gel. These alginate
'vaccination nodes' may thus have the potential for focusing and modulating the effector phase
of an immune response at a chosen peripheral tissue site, such as a solid tumor or site of
infection. In addition, these results highlight the potential interplay that may occur in a variety of
implant and tissue engineering settings between the well-studied biomaterial alginate and
ongoing host immune responses in vivo.
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Figure 3-1: Schematic outline of DC and lymphocyte trafficking in response to
injectable 'vaccination nodes.' When alginate encapsulating activated antigen-loaded DCs is
injected subcutaneously into mice, a few of the inoculated DCs migrate to the draining lymph nodes,
where they can prime antigen-specific T cells. Factors secreted by exogenous DCs within the
alginate recruit endogenous host DCs to the gel. Once T cell priming is initiated by the lymph node-
trafficking DCs, activated T cells are attracted back to the alginate matrix in response to the local
inflammatory milieu established in the gel.
3.2 Materials and Methods
3.2.1 Materials
Sterile alginates Pronova SLM20 (MW 75,000 - 220,000 g/mol, >50% M units), Pronova
SLM100 (MW 200,000 - 300,000g/mol, >50% M units), Pronova SLG20 (MW 75,000 -
220,000 g/mol, >60% G units), and Pronova SLG100 (MW 200,000 - 300,000g/mol , >60% G
units) were purchased from Novamatrix (FMC Biopolymers, Sandvika, Norway). All antibodies,
anti-mouse PE-TCR3, anti-mouse FITC-CD19, anti-mouse APC-CD1l c, anti-mouse APC-CD4,
and anti-mouse APC-CD8, and Growth-Factor-Reduced Matrigel were purchased from BD
Biosciences (San Jose, CA). 2, 2, 4-trimethylpentane (isooctane, ChromAR, 99.5%) was
obtained from Mallinckrodt Baker (Phillipsburg, NJ). Calcium chloride dihydrate and
lipopolysaccharide (LPS) from E. Coli was from Sigma-Aldrich (St. Louis, MO). CpG
oligonucleotides with a phosphorothioate backbone (CpG 1826, sequence 5' -
/5AmMC6/T*C*C* A*T*G* A*C*G* T*T*C* C*T*G* A*C*G* T*T - 3') were synthesized
by Integrated DNA Technologies. Mouse CCL21 and CCL19 recombinant chemokines and
ELISA detection kits were purchased from R&D Systems (Minneapolis, MN). SlY peptide
(SIYRYYGL) was synthesized at the MIT Biopolymers Laboratory. All the other chemicals
were purchased from Sigma unless otherwise stated.
3.2.2 CCL21 and CCL19 release from alginate in vitro
Release of the chemokine CCL21 or CCL 19 from alginate matrices was measured by an
ELISA assay. Alginate gels were formed by mixing 2 [pg mouse CCL21 or CCL 19 with alginate
solutions (150 tL of O.Olg/mL Pronova SLM20, SLM100, SLG20, or SLG100 in PBS pH 7.4)
and gelled by addition of 1% wt/vol CaCl 2 solution (30 1IL) in Eppendorf tubes. All samples
were allowed to gel at 37C for 1 hr while shaking, followed by a gentle wash with lmL of
complete RPMI 1640 medium supplemented with 10% FCS. Release studies were conducted by
adding lmL of complete medium to gels at 370 C; 950pL of supernatant was removed for
analysis at each time point over 7 days and fresh medium added to replace that withdrawn. The
supernatants were stored at 40 C until all the time points were collected, and on day 7 the alginate
gels were digested with 10mg/mL alginate lyase for -20 minutes at 370 C to recover all
remaining chemokine. The amounts of chemokine in supernatants from each sample were
quantified using an ELISA according to the manufacturer's instructions (R&D Systems).
3.2.3 Alginate particle synthesis and self-gelling alginate
Alginate microparticles were synthesized via a water-in-oil emulsion of alginate in an organic
solvent, as introduced in Chapter 2. 1.5mL of sorbitan monooleol (Span 80, Sigma) and 0.5mL
of Tween-80 (Sigma) were first added to 40mL of iso-octane under magnetic stirring, and
homogenized for 2 minutes using an UltraTurrax T25 homogenizer (IKA Works) at speed
8x1000/min. Pronova SLG20 solution (400 pL, 0.01g/mL in PBS) was then added drop-wise
and homogenized for 3 minutes, followed by addition of 251pL 5% wt/vol CaCl 2 solution to
crosslink the alginate. The resulting solution was homogenized for another 3 minutes, and the
resulting particles were recovered by centrifugation at 2060xg for 5 min. The iso-octane
supernatant was discarded, and the particle pellet was washed with 40mL of iso-octane. After
another centrifugation, the particles were re-suspended in lmL of deionized, distilled water and
washed three times. The particles were resuspended in deionized, distilled water with a final
volume of lmL and stored at 40C until used. Alginate particle size was determined from optical
micrographs taken with a Zeiss Axiovert 200 epifluorescence microscope at 40X and analyzed
with MetaMorph software (Molecular Devices).
3.2.4 Elemental analysis/quantification of Ca2 + ions in the alginate particles
Half a batch (500 pL) of the as-synthesized alginate microparticle suspension was centrifuged
down and the supernatant removed. The pellet was resuspended with 300 gL of 100 mM EDTA
(disodium EDTA dihydride) solution. Samples were analyzed using ICP-OES (inductively
coupled plasma optical emission spectroscopy) by Quantitative Technologies, Inc. (Whitehouse,
NJ).
3.2.5 Animals and cells
Animals were cared for in the USDA-inspected MIT Animal Facility under federal, state,
local and NIH guidelines for animal care. C57B1/6 mice and mice expressing green fluorescent
protein under the chicken [-actin promoter and cytomegalovirus enhancer (GFP expressed in all
cells except erythrocytes and hair follicles) were obtained from Jackson Laboratories. 2C TCR
transgenic mice on a RAG2' C57B1/6 background were a gift from Jianzhu Chen (MIT). Bone
marrow-derived dendritic cells were prepared by isolating bone marrow from tibia and femurs of
C57B1/6 mice or GFP' mice and culturing them in vitro over 6 days in the presence of 10ng/mL
GM-CSF in complete medium (RPMI 1640 containing 10% FCS, 2 mM L-Glutamine,
penicillin/streptomycin, and 50ptM 2-mercaptoethanol) following a modification of the
procedure of Inaba (99) as previously reported (100). The resulting dendritic cells were
activated/matured with 100 ng/mL LPS or 1 M CpG for 18 hrs and then washed thoroughly with
PBS before use. For in vivo T cell priming studies, the dendritic cells were pulsed with 10 jM
SIY peptide at the same time the maturation stimuli were added to the cultures.
3.2.6 In vivo immunization of mice
Matrix alginate Pronova SLM20 (160 tL of 0.01 g/mL alginate in PBS) was mixed with
factors to be delivered (i.e. total of 2x10 6 dendritic cells, 2 ptg CCL21, or 50 tM SIY peptide in
each gel) and kept on ice until injection. In the case of alginate mixed with CCL21, the
chemokine was mixed with alginate at 40 C overnight to allow association of the chemokine with
alginate chains. SLG20 alginate microspheres (100 jiL from the microsphere stock suspension,
-1x10 6 microspheres) was added to an eppendorf tube and centrifuged down to obtain a pellet.
The supernatant was gently removed from the tube and the microsphere pellet was vortexed and
mixed with the soluble alginate + cells/chemokine solution immediately before injection into
C57B1/6 recipient mice, and 150pL total was injected with an insulin syringe (30 gauge, BD
Biosciences) subcutaneously into the flanks of anesthetized mice. For intradermal and
subcutaneous injections of dendritic cells alone, 50OL of PBS with or without 2x10 6 dendritic
cells was injected either s.c. or i.d. into the back flanks of mice.
3.2.7 Confocal microscopy of gels explanted from mice
GFP+ C57B1/6 dendritic cells were washed 3X with PBS, mixed with alginate and injected s.c.
in anesthetized C57B1/6 mice. Animals were euthanized and DC-loaded gels were explanted
from mice 22 hrs after inoculation and imaged using a Zeiss LSM 510 confocal microscope. 3D
Z-section images were obtained through 100-300[tm depths in 4jtm z-steps using a 40x objective.
3.2.8 Histology
Explanted gels were fixed with formalin for 20 hours and embedded in paraffin. Thin
sections of 4jtm thickness were sliced and stained with heamatoxylin and eosin (H&E).
3.2.9 Adoptive transfer of 2C cells
Splenocytes were isolated from 2C TCR transgenic mice. For labeling, the splenocytes
(106/mL) were incubated with 10 [M carboxyfluorescein succinimidyl ester (CFSE) in serum-
free RPMI for 10 min at 370C, quenched with 5mL cold RPMI medium with FCS, and washed
3X in complete medium and PBS. Labeled cells (5x10 6) in 200 jtL sterile PBS were adoptively
transferred to anesthetized recipient C57B1/6 mice by retrorbital injection. The mice were then
immunized with alginate gels 24 hrs after adoptive transfer.
3.2.10 Flow cytometry analysis
Alginate gels, lymph nodes, and spleens recovered from immunized animals were digested
with 0.28 WU/mL Liberase Blendzyme 3 (Roche Applied Sciences) for 20 min at 370C,
followed by the addition of 0.02% EDTA and lmg/mL of alginate lyase (Sigma) or 55mM
sodium citrate (Sigma) for an additional 15 min to quench the collagenase activity and digest the
alginate. Digested gels were passed through 40jtm nylon mesh cell strainer (BD Falcon, San
Jose, CA) with 10mL of PBS. After centrifugation of the cell suspension, recovered cells were
resuspended in flow cytometry buffer (1% BSA, 0.1% NaN3 in Hank's balanced salt solution,
pH 7.4) at 4C, and blocked with 10 Vtg/mL anti-CD 16/CD32 antibody for 10 min. The cells
were then stained with fluorescent antibodies against surface markers for 20 minutes on ice,
followed by three washes with flow cytometry buffer and addition of 1.25ptg/mL propidium
iodide (PI) for viability assessment. Stained cells were analyzed on a BD FACSCalibur flow
cytometer. Enumeration of DCs/cellular infiltrates was performed by calibration of flow
cytometer events to cell suspensions of known concentration. Cell losses during the multiple
wash/treatment steps of gel and tissue digestions were reproducible and were accounted for in
the reported recovered cell numbers.
3.3 Results
3.3.1 Self-gelling alginate as a basis for vaccination nodes
In order to deliver dendritic cells (DCs) in vivo in a minimally-invasive manner, we
demonstrated the development of an injectable, biocompatible hydrogel that would crosslink in
situ to form a supporting matrix in Chapter 2. An ideal material for our application would in
addition be capable of reversibly binding chemokines and other supportive cytokines (either
produced by DCs in the gel or exogenously added to the matrix prior to injection), to facilitate
the retention of these factors in the local microenvironment and the generation of a pro-
inflammatory milieu to support host T cell and DC attraction to the matrix. Because of
alginate's anionic polysaccharide structure, we also hypothesized that it could support
chemokine/cytokine binding in a manner mimicking cytokine binding to native
glycosaminoglycans (GAGs), since many chemokines and cytokines bind to heparan sulfate and
related GAGs.
To test the ability of alginate to retain and slowly release chemokines via ionic interactions
with the polysaccharide chains, we first measured the in vitro release of two different T
cell/dendritic cell chemoattractants, CCL21 and CCL 19, from bulk alginate gels of different
composition (alginate G:M ratio) and molecular weight. Each of these chemokines is highly
cationic, with estimated net charges of +17 and +7 for CCL21 and CCL19, respectively (163).
Bulk calcium-crosslinked alginate gels (1 wt% alginate) were prepared with 2 tg chemokine per
1.5 mg alginate, and release from these gels into serum-containing medium at 370 C was recorded
over 7 days. As shown in Figures 3-2A and 3-2B, only a few percent of CCL21 encapsulated in
alginate gels was released over a week, whereas -60% of the less-highly charged CCL 19 was
released during the same period of time. The molecular weights of these two chemokines are
nearly identical (-9-12 KDa), suggesting a strong correlation between their net charge and
release rates from alginate. CCL21 release rates were also more sensitive to changes in the
molecular weight of the alginate and the G:M ratio of the polysaccharide compared to CCL19.
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Figure 3-2: Alginate gels reversibly
bind chemokines in vitro and in
vivo. (A, B) In vitro release of
chemokines from alginate gels:
Chemokines (2 pg of CCL21 (A) or
CCL19 (B)) were encapsulated in
alginates with varying molecular weight
and G:M ratios, and release of the
protein into serum-containing medium
was assessed over 7 days at 370C by
ELISA. Filled circle (*) = Pronova
SLM20 (MW 75,000 - 220,000
g/mol, >50% M units), filled square (m)
= Pronova SLM100 (MW 200,000 -
300,000g/mol, >50% M units), open circle
(o) = Pronova SLG20 (75,000 - 220,000
g/mol, >60% G units), open square (L) =
Pronova SLG100 (MW 200,000 -
300,000g/mol, >60% G units). (C)
Release of CC21 from 150 pL 'self-gelled'
alginate in vivo following subcutaneous
injection in C57BI/6 mice: Self-gelling
alginate mixed with 2 pg CCL21 or control
blank alginate was injected (150 pL) s.c. in
groups of 2 C57B1/6 mice per time point.
Gels were recovered after 2 d (unfilled
bars) or 7 d (dotted filled bars), digested,
and chemokine remaining in the gel was
measured by ELISA. Error bars = SEM.
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Based on these promising initial results for sustained release of chemoattractants from
alginate, we tested whether chemokines were retained/slowly released from self-gelled alginate
in vivo too (Figure 3-2C). Self-gelling alginate mixed with 2 ptg of CCL21 or control gels
lacking chemokine were injected s.c. in the flanks of C57B1/6 mice. Two or seven days post
injection, the alginate gels were recovered, digested with alginate lyase/collagenase, and the
amount of chemokine remaining was assessed by ELISA. As shown in Figure 3-2C, little or no
CCL21 was detected in control alginate gels (confirming no substantial chemokine contribution
from surrounding host tissue), but exogenously-added CCL21 was well retained over 7 days in
alginate: -90% of the chemokine initially injected was still present in the gels after 2 days, and
-50% still remained after 7 days. Thus, self-gelling alginate appears to reversibly bind and
slowly release chemokines both in vitro and in vivo.
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Figure 3-3: Activated dendritic cells persist several days in vivo within alginate matrices and
attract host DCs to the injection site. (A) Confocal microscopy images (at two different z depths) of
GFP* dendritic cells in self-gelled alginate matrices, explanted 22 hrs after s.c. injection in C57BI/6
mice. DCs with spread morphologies are highlighted by white arrows. Scale bars 50pm; z positions
are 75 pm (left image) and 120 pm (right image). (B) Flow cytometry scatter plots illustrating the
identification of GFP* cells (in bold rectangle, left panel forward scatter (FSC) vs. GFP fluorescence)
and dendritic cells (in bold rectangle, right panel MHC II vs. CD11c fluorescence) recovered from
alginate gels. (C-E) Groups of 3 mice per timepoint were injected with control alginate or alginate
carrying activated GFP* DCs. Gels were recovered at indicated times, digested, and recovered cells
were analyzed by flow cytometry. (C) Quantification of numbers of GFP* cells detected in alginate
gels as a function of time following injection of (o) control empty alginate or alginate carrying activated
GFP DCs (n). (D) GFP* DCs detected in draining lymph nodes (.) and spleens (A) over 7 d in vivo
following injection of self-gelling alginate carrying activated GFP DCs. (E) Total (endogenous +
injected) CD1 lc*MHCII* dendritic cells detected in self-gelling alginate matrices injected either with (m)
or without (o) activated DCs, and total number of recruited endogenous DCs (V). Error bars = SEM.
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3.3.2 DC delivery
In order to determine whether self-gelling alginate is able to harbor activated dendritic cells
following injection, bone marrow-derived DCs from transgenic GFP + mice were prepared. GFP
expression serves both as a fluorescent marker of the identity of the injected DCs as well as a
marker of their viability (164). GFP+ DCs were activated by treatment with CpG
oligonucleotides (ligands for the DC-activating receptor Toll like receptor-9), washed thoroughly,
then mixed with alginate solution and Ca2+-loaded microspheres and injected s.c. into the flanks
of C57B1/6 mice (2x106 DCs in 150 gL alginate). Twenty-two hours post injection, the gels
were explanted and examined by confocal fluorescence microscopy. As shown in Figure 3-3A,
GFP + dendritic cells were able to adhere and spread within the gel over this timeframe in vivo.
Some cells were also observed to be actively migrating through the gel when observed in time-
lapse (data not shown). Activated DCs are known to have a short lifespan of only a few days
(165, 166), and many fewer GFP + cells were detectable by confocal microscopy in gels
explanted after 7 days (data not shown).
Previous studies investigating the fate of dendritic cells following administration as DC
vaccines have shown that following bolus s.c. or intradermal injection of free cells, many DCs
remain at the injection sites for several days, even though activated DCs express the chemokine
receptor CCR7 that guides homing to lymphatics and draining lymph nodes (157, 167-169). In
order to track the lifespan and location of DCs injected in alginate vaccination nodes, GFP +
dendritic cells were activated with LPS for 18 hrs, then 2x1 06 cells were mixed with self-gelling
alginate and injected s.c. in C57B1/6 mice. The gels, spleens, and draining lymph nodes of
injected mice were isolated on days 2, 4, or 7, digested, and recovered single cell suspensions
were stained with antibodies for cell surface markers and analyzed by flow cytometry. Injected
DCs at each location were detected via GFP fluorescence, while the total number of recovered
dendritic cells (both injected cells and endogenous host DCs) present at the site/organ was
identified on the basis of CD1 1c and MHC II co-expression, as shown in Figure 3-3B. At 1 hr
following injection, -25% of the injected DCs could be recovered from gels (Figure 3-3C). By
two days post-injection, about -15% of the inoculated dendritic cells were still present in the
alginate gel and their numbers continued to decline to -0 by day 7 (Figure 3-3C), due to death of
the short-lived activated cells and/or emigration from the matrix. The total number of GFP+
cells detected in the draining lymph nodes or in the spleens peaked on day 2, and declined over
the ensuing 5 days (Figure 3-3D). The relatively low numbers of exogenous DCs detected
migrating from gels to draining lymph nodes were comparable to findings in prior studies in
which purified mouse dendritic cells were injected s.c. as free cell suspensions (168).
Importantly, even such low numbers of DCs have been implicated in initiation of potent immune
responses (167-169).
Dendritic cells can transfer membrane, antigen, and even intact peptide-MHC complexes to
other DCs through direct contact or through release of vesicular structures known as exosomes
(170, 171); thus host DCs can play a major role in the immune responses elicited by injected DC
vaccines. Strikingly, though the number of exogenous DCs in alginate gels quickly decayed over
1 week following injection, host DCs were rapidly recruited to the alginate matrix in response to
the presence of the injected cells and alginate. As shown in Figure 3-3E, the infiltrate of the
host CD 11c+MHCII + dendritic cells (injected and endogenous) was sustained over 7 days, by
which time nearly all of the DCs present in the alginate were host cells, constituting -6% of the
total cellular infiltrate in gels at this timepoint. While the initial presence of exogenous DCsfacilitated the recruitment of CD 11 c+MHCII+ DCs during the early time points, the steady
immigration of host CD 11 c+MHCII in empty alginate also elucidates the importance of alginate,
acting synergistically with the exogenous DCs, in the host DC recruitment. To determine if thisincreased number of host DCs attracted to activated-DC-carrying gels was limited to
accumulation of host cells at the edge of gels in a classic foreign body-type response or involved
direct migration of cells into the matrix, we injected gels loaded with unlabeled mature DCs intoGFP+ mice. 3D optical sectioning of gels explanted 2 or 7 days after injection showed that GFP
host cells (some with obvious dendritic morphology) had infiltrated into the gels as far as
confocal imaging could clearly resolve (-100 p~m into gels, data not shown). Thus, injected
activated DCs are rapidly lost from the alginate vaccination nodes, with a small number
trafficking to lymph nodes, while host DCs rapidly replace these cells and remain in the gels
over at least 7 days.
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Figure 3-4: Alginate matrices carrying mature DCs chemoattract T cells in vivo. Self-gelling
alginate carrying dendritic cells or control 'empty' gels were injected s.c. in C57B1/6 mice (groups of 5-8 mice per timepoint), recovered at different time points, and analyzed by flow cytometry andhistology. (A, B) Flow cytometry analysis of cells recovered from gels after 7 d in vivo and stained withantibodies against the T cell receptor (TCRI) or CD19 (a B cell marker). Control 'empty' alginate
elicited minimal T cell infiltration (A) but alginate carrying CpG-matured dendritic cells attracted asubstantial T cell infiltrate (B). (C, D) H&E-stained histological sections of gels 7 d following injection:(C) control empty alginate, (D) alginate carrying mature dendritic cells. (scale bars 100pm). (E)Quantification of total T cell infiltrate after 7 d in vivo in control empty alginate gels, gels loaded with
mature DCs (mDCs) or gels loaded with 2 pg CCL21 (CCL21). Each open circle represents the
response in an individual mouse (* statistically significant differences, p<0.05, Dunn's multiple
comparison test). (F) Quantification of CD4 T cell (open portion of bars) and CD8 T cell (hatchedportion of bars) infiltration of alginate gels carrying immature (alg+iDC) vs. mature DCs (alg+mDC) at 7and 20 d post-injection. (* statistically significant differences p<0.05 by one-tailed unpaired Student's ttest). Error bars = SEM. (G) Comparison of T cell attraction to different sites of DC injection: alginategels carrying mature DCs (alg), intradermal injection of free mature DCs (i.d.), or subcutaneousinjection of free mature DCs (s.c.). (* significant differences p<0.05 by one-tailed unpaired Student's ttest).
3.3.3 T cell recruitment
For alginate vaccination nodes to be effective in directing the physical locale of an immune
response, the attraction of both DCs and host T cells to alginate gels would be a key event.
Activated DCs secrete several chemokines known to attract T cells (172-174), and thus we
hypothesized that DCs would promote T cell infiltration of alginate vaccination nodes. In order
to investigate T cell attraction to alginate matrices, self-gelling alginate gels with or without
CpG-matured DCs were injected s.c., and gels were recovered and digested after 2 or 7 days for
analysis of cellular infiltrates. Cells recovered from gels were antibody stained to detect
expression of T cell receptor (TCR), CD 11 c (as a marker of DCs), and CD 19 (as a marker for B
cells) and analyzed by flow cytometry. As shown in Figures 3-4A and 3-4B, by day 7 alginate
containing CpG-matured dendritic cells elicited a greatly increased infiltration of T cells relative
to control alginate lacking DCs, making up -30% of the total infiltrate. Few if any B cells were
detected in either case. Hematoxylin/eosin-stained histological sections of alginate gels
recovered after 7 days showed a substantially increased cellular infiltrate within gels injected
with activated DCs (Figure 3-4D) compared to control alginate (Figure 3-4C). Quantification of
total T cells attracted to gels (Figure 3-4E) showed an 8-fold increase in the total number of T
cells present in mature DC-carrying gels vs. 'blank' alginate. This increase in T cells in the gels
was not simply a nonspecific increase in all inflammatory cells, as the total number of cells
recovered from alginate gels carrying mature DCs was only 2-fold over 'blank' alginate gels on
day 7 (data not shown). Interestingly, delivery of the strong T cell chemoattractant CCL21 by
mixing 2 Cpg CCL21 with alginate prior to injection as a non-cellular alternative could not
substitute for activated DCs in driving T cell attraction to the gels (Figure 3-4E). Although the
number of T cells recruited to alginate gels carrying CCL21 was increased compared to control
blank alginate on day 2 (data not shown), the effect of the chemokine alone was not statistically
significant by day 7 (Figure 3-4E). We also compared alginate gels injected with activated DCs
or immature (non-activated) DCs to determine whether DC maturation was important for the T
cell recruitment response. Injection of immature DCs in alginate attracted few T cells by 7 days
(not statistically different from blank alginate), but by 20 days post injection, T cell infiltration
into gels that had initially harbored immature (iDC) or mature DCs (mDCs) was essentially
identical and T cells made up nearly 50% of the total cellular infiltrate (Figure 3-4F and data not
shown). On day 7, about 19% of the total T cells recovered were CD8 T cells in alginate +
mDC gels; CD8 T cells increased to -31% of the total T cell population by day 20. Altogether,
alginate vaccination nodes carrying activated dendritic cells rapidly recruited both host T cells
and dendritic cells to the matrix, and these cellular infiltrates were sustained over more than three
weeks in vivo.
To determine whether the alginate matrix and activated DCs have a synergistic role in the
attraction of host T cells, we compared T cell infiltration into DC-loaded alginate gels with T cell
infiltration into s.c. or intradermal tissue sites where activated DCs were injected alone in saline.
Intradermal injection of activated DCs, which is one of the most promising routes of DC
administration in dendritic vaccines, has been reported to elicit some T cell attraction to the
injection site detectable by histology (157). Figure 3-4G shows that at least 125-fold more T
cells were recovered from DC-carrying alginate gels than from s.c. or i.d. sites of DC-only
injection. Moreover, the T cell recruitment phenomenon observed in gels carrying DCs was not
a result of a nonspecific response against massive dead cells at the injection site, as confirmed by
injection of apoptotic and necrotic DCs in the gels that showed inferior attraction of T cells to the
gel site (Figure S2, Appendix B.1). This result illustrates the unique T cell recruitment response
elicited by dendritic cell vaccination using alginate gels.
3.3.4 T cell priming and re-trafficking
The data shown above demonstrate the attraction of host T cells and dendritic cells to
activated DC-loaded alginate matrices. Once T cells and DCs are brought together, the key
function of activated DCs is to present antigenic peptides to T cells and initiate T cell priming.
To determine whether antigen-loaded dendritic cells delivered in alginate gels could initiate
priming of na've T cells and to track the evolution of a T cell response initiated by alginate
vaccination nodes, we used an adoptive transfer model to create a defined antigen-specific T cell
population in host mice (schematically described in Figure 3-5A). In these experiments, CFSE-
labeled T cell receptor (TCR)-transgenic 2C splenocytes, whose T cells express a TCR that
recognizes the peptide sequence SIYRYYGL (SIY peptide) bound to H-2Kb class I MHC, were
adoptively transferred into syngeneic C57B1/6 mice, allowing the labeled T cells to take up
residence in the lymph nodes and spleen of the recipient animals and recirculate through the
blood along with the endogenous T cell population. The adoptively-transferred cells can be
identified ex vivo by staining with the antibody 1B2 (a monoclonal antibody that specifically
recognizes the 2C TCR (175)) and by CFSE fluorescence. As shown in Figure 3-5B, flow
cytometric analysis of cells recovered from lymph nodes of animals receiving 2C T cells reveals
a clearly detectable population of 1B2+CFSEhi cells, representing na've, undivided 2C T cells
(-0.3% of the CD8+ T cell population in lymph nodes). Activation and proliferation of these T
cells in vivo leads to halving of the CFSE fluorescence level on each cell division, such that
divided cells are distinguished by steadily decreasing levels of CFSE fluorescence (illustrated in
Figure 3-5B, right panel).
To assess antigen-specific T cell priming in this system, CFSE-labeled 2C cells were
transferred to groups of recipient C57B1/6 mice. Twenty-two hours later, these recipient mice
were immunized s.c. on the flank with alginate containing activated dendritic cells that had been
loaded with SIY peptide in vitro. Control gels lacking DCs were injected on the opposite flanks
of the same mice (Figure 3-5A). Gels, draining lymph nodes, and spleens of the mice were
harvested on day 3, day 5, or day 7 following immunization to analyze the kinetics and
localization of the SIY-specific 2C T cells over time.
Figure 3-6A shows representative flow cytometry plots of 1B2 expression vs. CFSE
fluorescence levels for cells recovered from the secondary lymphoid organs and alginate gels
following immunization with DC-loaded alginate, summarizing the timecourse of 2C T cell
responses. The scatter plots show events gated on live cells (propidium iodidelow) for gel
samples and gated on CD8 + cells for secondary lymphoid organs; CD8+ cells constituted -30%
of the LNs and -20% of the spleens. 1B2 + 2C T cells detected in each sample are highlighted by
overlaid bold rectangles on the scatter plots. By day 3 following immunization with alginate gels,
adoptively transferred 2C cells were readily detected in lymph nodes (LNs) and spleen, but few,
if any, cells had entered alginate gels (with or without injected DCs); the 2C T cells had not yet
begun to undergo cell division in response to the immunizations. (The few 1B2+CFSE lW cells in
the day 3 plots from lymph nodes and spleens arise from a low nonspecific background staining,
as confirmed by control staining of wild-type, non-adoptively transferred spleens and lymph
nodes (data not shown)). Five days post immunization, priming and proliferation of 2C cells was
strongly evident in the draining LNs and activated CFSElow 2C T cells were detected in the
spleens of immunized mice. Still very few 2C cells were detected in the alginate gels; these
results indicate that priming of the antigen-specific T cells is initiated by DCs in the draining
lymph nodes- either injected SIY-DCs that migrated from the alginate gel to the LNs, or SIY
peptide carried to LNs by host DCs attracted to the injection site.
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Figure 3-5: Adoptive transfer model for tracking antigen-specific T cell responses following
vaccination node immunization. (A) CFSE-labeled 2C splenocytes were retro-orbitally injected
into wild type C57BL/6 mice, and 22 hrs later the mice were immunized with control alginate on the
left flank and alginate containing activated, SlY peptide-pulsed DCs on the right flank. The gels,
inguinal lymph nodes, and spleens were then isolated at various timepoints after immunization for
flow cytometry analysis. (B) Flow cytometry scatter plots (gated on CD8* cells) illustrating
detection of naTvel B2+CFSEbi ght 2C cells in lymph nodes following adoptive transfer (before
immunization), and dividing 1 B2* CFSE ' w'in teaene  2C cells which are in the process of being
primed/activated following immunization.
Seven days post immunization, a robust CFSE1oWlB2 + 2C effector T cell population was
detected in alginate gels that had been initially injected carrying SIY-pulsed DCs, but not in
control 'blank' gels from the opposite flanks of immunized mice. Figure 3-6B shows the
percentage of CD8 T cells and 2C T cells that infiltrated the control alginate and alginate+SIY-
DC samples by day 7, showing that a large fraction of the CD8+ T cells that infiltrate the gels are
2C T cells. The lack of activated 2C T cell recruitment to the control gels indicates that 2C T
cell homing to the alginate+SIY-DC gels is not a nonspecific attraction as part of the host
response to alginate alone, but is rather dependent on the presence (initially) of the activated
exogenous DCs, the SIY antigen, or both. To distinguish between these possibilities, a control
experiment was performed where mice with adoptively-transferred 2C T cells were immunized
on one flank with alginate carrying activated DCs (but lacking SIY peptide) and on the opposite
flank with alginate carrying free SIY peptide but no DCs. In these animals, T cell priming had
already initiated in the LN by day 2 as some of the soluble SIY peptide drained to the lymph
nodes (data not shown). By day 7, a few 2C T cells migrated to alginate containing activated
(antigen-free) DCs, but to a much lesser extent than when the DCs had been loaded with SIY
(data not shown). Likewise, few 2C T cells migrated to the alginate gels carrying free SIY
peptide (Figure 3-6C and data not shown). Thus, although host DCs could theoretically infiltrate
the SIY peptide-loaded gel and present the peptide to infiltrating T cells, the early presence of
activated, antigen-bearing DCs following injection appears to set the stage for enhanced
attraction of effector T cells to the gel.
The data from these studies suggests the overall chain of events outlined in Figure 3-1 for a
single immunization with alginate 'vaccination nodes:' T cell priming is initiated in the draining
lymph nodes, either by the small number of injected DCs that migrate out of the alginate and
reach the draining LNs, or by host DCs that infiltrate the alginate and pick up antigen from live
or dying injected DCs. Importantly, the presence of activated antigen-pulsed DCs in the gels
conditions the vaccination node to become a site for directed homing/accumulation of activated
antigen-specific T cells following their initial priming in the draining lymph nodes. The ability
of this vaccination node approach to elicit priming of na've T cells and then direct their
trafficking to a defined site may allow this system to focus the effector phase of the immune
response at a target site, such as tumors or sites of persistent infections.
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Figure 3-6: Dendritic cells delivered in alginate gels initiate T cell priming in draining lymph
nodes and recruit activated T cells to the alginate matrix. (A) Flow cytometry scatter plots (CFSE
vs. 1B2) tracking the temporal evolution of 2C T cell activation and trafficking following immunization
with alginate gels. Shown are analyses of cells recovered from control alginate, alginate carrying
peptide-pulsed mature DCs, inguinal lymph nodes, and spleens show the biodistribution and cell division
on days 3, 5, or 7 after gel injection. Heavy boxes highlight 1B2 + 2C T cells recovered from each
sample. (B) Quantification of 2C T cells as a percent of all live cells recovered (open bars) and total
CD8 T cells as a percent of all live cells recovered (dotted bars) in control alginate and alginate carrying
SIY-pulsed mature DCs on day 7 (n = 2 mice per condition). (C) In a control experiment, mice that had
received CFSE-labeled 2C T cells were injected on one flank with alginate carrying SIY-pulsed DCs and
on the other flank with alginate carrying SlY peptide alone. Error bars = SEM. Data are from one
representative of two independent experiments.
3.4 Discussion
In this chapter, the ability of an injectable alginate hydrogel to support the delivery of
dendritic cells and initiate antigen-specific T cell priming for vaccination or immunotherapy was
demonstrated. The choice of an appropriate matrix to deliver DCs in this application was
dictated by the desire for a biocompatible, injectable material capable of binding factors secreted
by DCs to promote their concentration within the matrix, but which would eventually dissolve
over time to provide temporal control over this DC delivery-based therapy. Based on these
criteria, we found alginate to be an attractive basis for this system, as described in Chapter 2. In
addition to its biocompatibility, alginate's anionic structure mimics the presence of negatively
charged sugars such as heparan sulfate in the native extracellular matrix environment.
Chemokines (and cytokines) in vivo are known to interact with and bind cell surface and ECM
glycosaminoglycans such as heparan sulfate, creating haptotactic gradients of immobilized
chemokines. Matrix binding is thought to be important in the cell-guiding properties of many
chemokines in vivo and for regulating cell behavior (176-178). We hypothesized that alginate
matrices would support chemokine/cytokine immobilization to favor the concentration and
retention of factors released by DCs in the matrix. In fact, alginate gels reversibly bound
positively charged chemokines and provided sustained release of leukocyte attractant molecules
(Figure 3-2). The release of CCL21 and CCL19 from alginate was strongly dependent on their
effective net charge, indicating a dominant effect of charge-charge interactions on the release
rate of these molecules.
To apply this system in vivo, we utilized a self-gelling alginate formulation obtained by
mixing soluble alginate with calcium-crosslinked alginate microspheres. Alginate with a high G
content (SLG20) was used for the microspheres, enabling high levels of calcium ions to be
loaded into each microsphere; alginate with a high M content (SLM20), which forms
mechanically softer gels, was used for the matrix alginate to favor cell infiltration. When
compared with other injectable biopolymers such as collagen and Matrigel in pilot studies,
alginate demonstrated substantially greater mechanical stability, which allowed reproducible
quantitative analysis of cellular infiltrates (data not shown).
In addition to reversibly binding chemokines, self-gelling alginate was able to harbor
exogenously injected dendritic cells (Figure 3-3A), allowing them to spread and adhere as well
as migrate inside the matrix (not shown). Since mammalian cells have been previously reported
to exhibit little or no adhesion to alginate gels (103, 179), it is possible that adhesion proteins
(e.g., secreted by local stromal cells) are deposited in these matrices in vivo over time, enhancing
cell adherence and migration in situ. However, we have also observed that freshly isolated
splenocytes migrate in self-gelling alginate in vitro (data not shown), which may imply that
leukocytes possess the ability to migrate through alginate gels via a mechanism independent of
integrins or other common adhesion molecules. Along these lines, T cells have been observed to
migrate through fibrillar collagen gels even in the presence of blocking antibodies against the
known lymphocyte integrins (180, 181) or in the total absence of functional integrins (139).
One of the factors determining the efficacy of dendritic cell vaccines is the route of
administration of antigen-loaded DCs, and studies of DC immunization have suggested that the
majority of inoculated cells remain at the injection site (167-169). Of the few DCs that do
migrate away from the injection site, Eggert et al. (164, 167) showed that subcutaneously or
intradermally injected DCs migrate preferentially to the draining lymph nodes. In order to track
the trafficking of DCs following injection in our alginate gel system, we generated and injected
GFP mature dendritic cells. In agreement with earlier studies (164, 168), the total number of
inoculated DCs detected in draining lymph nodes peaked 2 days after s.c. injection (Figure 3-3D).
Many dendritic cells also remained within the gels over several days (Figure 3-3C). One of the
challenges of DC vaccines is to prolong the period of time MHC-peptide-complexes are
displayed by short-lived activated DCs (182), and if alginate can act as a local depot for protein
antigen or peptide-MHC complexes which can be transferred to attracted host DCs, this might
sustain stimulation of effector cells. Notably, despite the steady loss of injected DCs, the total
number of CD 11 c MHCII cells in DC-carrying gels remained nearly constant over the first
week in vivo (Figure 3-3E).
In addition to recruiting a large number of host antigen presenting cells, we examined whether
dendritic cells delivered with self-gelling alginate in vivo recruit T cells to the injection site, as
the generation of antigen specific effector T cells and their proper trafficking are crucial to
successful dendritic cell vaccines. Activated DCs secrete a number of chemoattractants for T
cells (172-174), and histological analysis of human patients receiving intradermal injections of
DCs has shown evidence for specific attraction of T cells to sites of DC injection (157). Alginate
by itself elicited minimal T cell infiltration, but in the presence of mature dendritic cells, large
numbers of T cells were attracted to these matrices, with both CD4+ (-70-80%) and CD8 + (-20-
30%) T cells present (Figure 3-4). Compared to standard immunization regimens where free
DCs are injected in s.c. or i.d. sites, more than 100-fold greater levels of T cells were drawn to
alginate matrices loaded with DCs relative to free DC injection at native tissue sites. The T cell
infiltrate in the presence of DCs persisted for over 20 days in vivo (Figure 3-4F) until the alginate
gels dissolved (data not shown). Because the time for dissolution of alginate gels can be readily
manipulated by changes in the crosslinking and molecular weight of the alginate chains (80, 103),
it should be possible to specifically design these gels to last for requisite time periods and
maintain T cell localization at chosen peripheral tissue sites for defined periods.
Given that mature dendritic cells were able to attract both T cells and host dendritic cells to
alginate gels, we examined whether antigen-pulsed dendritic cells delivered in alginate could
initiate an immune response and redirect effector T cell trafficking to the gels. Analysis of the
cell division profile of a labeled, adoptively-transferred clonal T cell population over time in vivo
indicated that T cell activation following alginate gel/DC immunization was initiated in the
draining lymph nodes, followed by migration of primed T cells to the spleen and alginate matrix
site which initially contained exogenous mature dendritic cells. Whether further priming and
proliferation of T cells take place within the gels is yet to be verified, though we have detected
elevated levels of interferon-y in these gels (data not shown). The majority of T cells that homed
to alginate gels containing SIY-pulsed DCs were 1B2 + 2C cells (Figure 3-6C), demonstrating the
antigen-specific nature of the effector cell retrafficking to these sites.
Based on these findings, we hypothesize that attraction of primed, antigen-specific T cells to
DC-loaded alginate gels can be used to redirect the physical locale of the effector phase of an
immune response. For example, injection of DC-loaded alginate gels around solid tumors may
allow host DCs and anti-tumor T cells to be concentrated in the tumor microenvironment.
Factors can be delivered from alginate matrices to counter immunosuppressive factors secreted
from the tumor microenvironment. The feasibility of co-delivering supportive factors (e.g.,
inflammatory cytokines, Toll-like receptor ligands, etc.) in the alginate matrix provides
numerous means to locally foster an anti-tumor immune response using this system.
3.5 Summary
The overall efficacy of dendritic cell vaccines depends on multiple factors, including the state
of dendritic cell maturation, the dose of antigens, the choice of adjuvant, the route of
immunization, effector cell re-trafficking, etc. Here in this part of the thesis work we have
shown that 'vaccination nodes,' injectable alginate gels carrying dendritic cells, are able to
initiate an immune response with DCs acting as a physiological adjuvant for antigen delivery,
while simultaneously conditioning the alginate matrix to guide effector immune cells to migrate
to the gel. We thus believe vaccination nodes combine the T cell priming potential of dendritic
cell vaccines with the ability to guide the traffic of effector cells to desired tissue sites.
3.6 Acknowledgements
The work presented in this chapter was supported in part by the Defense Advanced Research
Projects Agency and the 3M Innovation Fund. We would like to thank the Division of
Comparative Medicine Histology Lab at MIT for helpful discussions/advice and assistance with
histological analyses.
Chapter 4
APPLICATION OF VACCINATION
NODES TO TUMOR THERAPY
With the understanding that self-gelling alginate can deliver
immunostimulatory/immunomodulatory factors of different nature in a sustained manner both in
vitro and in vivo, and allows easy cellular infiltration, together with the observations that the
synergy between alginate and activated dendritic cells can generate and re-focus immune
responses to a desired peripheral injection site, we examined the application of these vaccination
nodes to tumor settings. In order to augment the efficacy of the vaccine, the delivery of IL- 15
superagonist complex from the self-gelling alginate was explored. The robust nature of self-
gelling alginate also allowed us to study the types of cells at the local tumor sites that contribute
to efficient and successful control of tumor growth.
4.1 Introduction
Local therapies for cancer are of interest for treating unresectable metastases and/or for
treating sites of resection to combat local recurrence (183-185). Most immunotherapy strategies
seek to promote the robust infiltration of tumors with functional immune cells to promote tumor
destruction. However, defects in tumor vasculature, suppressive signals produced by tumor cells
or co-opted tumor-resident immune cells, and rapid tumor growth can limit the accumulation of
activated and competent immune cells (186, 187). Recently, combinations of cytokine,
chemotherapy, and/or immunostimulatory ligand treatments used to locally treat established
tumors have shown promise in not only eliminating treated tumors but also generating systemic
immunity capable of destroying large distal tumors (49, 69, 133, 188-190). However, such
powerful treatments may need to be coupled with methods to control delivery of these potent
immunoregulatory factors and limit systemic toxicity (191, 192). Prior work has demonstrated
that controlled release of immunocytokines from gels or microparticles at a tumor site can
enhance local immunotherapies, by sustaining the intratumoral concentration of these factors
while reducing systemic exposure following a single injection (67, 124, 193). Thus, the use of
biomaterials to deliver local combinatorial immunotherapies may lead to further enhancements
in the potency and safety of such treatments.
In the previous chapters, we described an injectable gel formulation of alginate, which
can be loaded with exogenous immune cells, proteins, or immunoregulatory factors. Alginate
has been studied extensively as a matrix for cell therapy and tissue engineering, and has been
shown to be safe for use in patients (194-196). We found that injection of alginate gels with
embedded activated dendritic cells in healthy mice elicits a sustained infiltration of host T-cells
and dendritic cells into the matrix, and that these matrices can release encapsulated cytokines
over a period of 7-14 days (197, 198). We hypothesized that a similar recruitment of
lymphocytes and DCs to alginate gels surrounding established tumors could promote local
antigen presentation and provide a local reservoir of immune cells for tumor invasion supported
by immunoregulatory factors released from the gel. To test this concept, we surrounded
established melanoma tumors with DC/cytokine/TLR ligand-loaded gels, and analyzed tumor
growth and the recruitment of leukocytes to the tumor-engulfing gels and the tumors themselves.
A single injection of alginate ECMs carrying DCs and the immunoregulatory cytokine IL-15
superagonist (IL-15SA) concentrated the cytokine within the tumor and led to prolonged
control/regression of established melanomas. Importantly, immune cell recruitment into
peritumoral gels correlated with infiltration of the adjacent tumor. Because these gels were
stable at least one month in vivo, they were readily recovered post-treatment to monitor the
composition of the tumor-local cellular infiltrate. We found that immune cell accumulation
within these peritumoral ECMs was substantial only under conditions where tumor growth was
strongly suppressed, and was completely lacking in mice where tumor growth was progressing.
4.2 Materials and Methods
4.2.1 Materials
Sterile alginates Pronova SLM20 (MW 75,000-220,000 g/mol, >50% M units) and Pronova
SLG20 (MW 75,000-220,000 g/mol, >60% G units) were purchased from Novamatrix (FMC
Biopolymers, Sandvika, Norway). Anti-mouse FITC-TCRP, anti-mouse PE-I-Ab, anti-mouse
APC-CD1 1c, anti-mouse APC-CD8a, anti-mouse APC-CD4, anti-moue FITC- and PE-NK1.1
were purchased from BD Biosciences (San Jose, CA). APC-tetramer ova-MHC I was from
Beckman Coulter (Fullerton, CA), anti-mouse PE-CDcS antibody was from Invitrogen (San
Diego, CA), and anti-mouse foxp3 staining kit was from eBioscience (San Diego, CA).
Isooctane was obtained from Mallinckrodt Baker (Phillipsburg, NJ). Calcium chloride dihydrate
and alginate lyase were from Sigma-Aldrich (St. Louis, MO). CpG oligonucleotides with a
phosphorothioate backbone (CpG 1826, sequence 5'-
/5AmMC6/TCCATGACGTTCCTGACGTT-3') were synthesized by Integrated DNA
Technologies. Mouse IL-15 and mouse IL-1 5Ra-human Fc chimera recombinant proteins and
ELISA detection kits were purchased from R&D Systems (Minneapolis, MN).
4.2.2 Animals and cells
Animals were cared for in the USDA-inspected MIT Animal Facility under federal, state,
local and NIH guidelines for animal care. C57B1/6 mice were obtained from the Jackson
Laboratory. Bone marrow-derived dendritic cells were prepared following a modification of the
procedure of Inaba (99) as previously reported (100). DCs were activated/matured with 1pM
CpG and pulsed with 1 pg/mL each of ova class I and ova class II peptides (Anaspec, San Jose,
CA) for 18 hrs and washed 3X with PBS before use. B16-ova cells based on the B16FO parental
melanoma line were transfected with ovalbumin expressed as an MSCV vector with puromycin
resistance, followed by an IRES and Ovalbumin-2A-green fluorescent protein (GFP). The ova
expressed in these cells lacks the first 55 amino acids (deleting the secretion signal) and is
soluble in the cytoplasm.
4.2.3 Calcium reservoir microsphere synthesis and self-gelling alginate
Alginate microspheres were synthesized as described in the previous chapters, by emulsifying
a 1% solution of SLG20 alginate in isooctane followed by the addition of aq. CaC12 to crosslink
the alginate. The resulting particles were washed with water and stored at 4C until use.
4.2.4 Tumor inoculation and alginate gel therapy
Except where noted otherwise, anesthetized C57B1/6 mice were inoculated with 3x10 4 B16-
ova cells s.c., which were allowed to establish for 14 days. IL-15 superagonist (IL-15SA) was
prepared by incubating 5 jig IL-15 and 31.7 lig IL-15Ra/Fc (equimolar amounts) at 370 C in 15.9
L PBS for 30 min. Matrix alginate (160 pL of 0.01 g/mL SLM20 alginate in sterile PBS at 40 C)
was mixed with factors to be delivered (e.g., 2x10 6 dendritic cells, 36.7 jlg IL-15 SA, and/or 80
jlg CpG in 150 pL gel) and kept on ice until injection. Calcium-loaded alginate microspheres
were synthesized as previously described (94, 198). Endotoxin levels in the alginate
preparations were well below levels stimulatory for innate immune cells (97), as described
previously (198). The Calcium-loaded microspheres (-1x106) were mixed with the matrix
alginate solution and 150 iL of the mixture immediately injected s.c., surrounding tumors. For
i.p. injections, 36.7 Lg of IL-15SA was injected in 200 jLL of PBS, and for i.t. injections, the
same amount of IL-15SA and 2 x 106 dendritic cells were injected into tumors in 30PL of PBS.
4.2.5 Flow cytometry analysis
Alginate gels, lymph nodes, and spleens recovered from treated animals were digested with
0.28 WU/mL Liberase Blendzyme 3 (Roche Applied Sciences, Indianapolis, IN) and 1 mg/mL of
alginate lyase (Sigma) for 20 min at 370C. Digested gels and tissues were passed through a 40
pm nylon mesh cell strainer (BD Falcon) with 9 mL complete RPMI medium. Recovered cells
were resuspended in FACS buffer (1% BSA, 0.1% NaN3 in Hank's balanced salt solution, pH
7.4) at 4C, blocked with anti-CD 16/32 antibody for 10 min, then stained with fluorescent
antibodies for 20 min on ice, followed by 3 washes with FACS buffer and addition of 1.25jpg/mL
propidium iodide (PI) for viability assessment. For foxp3 staining, cells were first stained with
Live/Dead Fixable Dead Cell Stain Kit (Invitrogen), and then fixed, permealized, and stained
according to the manufacturer's instructions (eBioscience). Stained cells were analyzed on a BD
FACSCalibur flow cytometer. Enumeration of cellular infiltrates was performed by calibration
of flow cytometer events to cell suspensions of known concentration, and cell frequencies
determined from a live cell gate with low PI staining. Cell losses during the multiple
wash/treatment steps of gel and tissue digestions were reproducible and were accounted for in
the reported recovered cell numbers.
4.2.6 IL-15Ra release in vitro and in vivo
Soluble IL-15Ra/Fc (15.9 pg, 2 mg/mL in PBS) was mixed with 80 [LL of alginate matrix
solution (0.0lg/mL in PBS), and then gelled with 5x10 5 calcium-loaded alginate microspheres to
crosslink the alginate in an epppendorf tube for 2 hrs at 37 oC. RPMI medium with 10% FCS
was added (500 tL) and cytokine release was assessed by ELISA analysis quantifying IL-1 5Ra
in the supernatant at staggered time points. The release of the IL-15SA was quantified in vivo by
injecting alginate gels carrying 36.7 jtg IL-15SA (31.7 jig IL-15Ra-Fc + 5 ig IL-15) around 14
day-old B16-ova tumors in C57B1/6 mice. Gels and tumors were recovered from independent
mice at staggered times, digested using the same digestion protocol as used for flow cytometry
analyses, or by using T-Per Tissue Protein Extraction Reagent (Pierce, Rockford, IL)
supplemented by Halt Protease Inhibitor Cocktail (Pierce) according to the manufacturer's
instructions. The digestion supernatants were collected and the amount of IL- 15 SA was
quantified by using IL-15Ra ELISA kit or two-site IL-15Ra/IL-15 ELISA. Loss of a fraction of
IL-15SA due to the digestion process was accounted for using control digestions with known
quantities of IL-15SA added and were accounted for in the analysis.
4.2.7 IL-15 superagonist immobilization on protein A-coated beads
The cytokine (5 jtg per gel) and the receptor alpha chain (31.7 jtg per gel) were pre-
complexed (at 2 mg/mL in PBS) for 30 min at 37 "C, after which the solution was mixed with 1
million Protein A-coated beads (Bangs Laboratories, Rockford, IL) in order to partly mimic the
presentation of IL-15 by IL-15Ra on cell surfaces (199). The Protein A-coated polystyrene
beads (-10 jtm diameter) captured the Fc portion of the IL-15Ra/Fc chimera to present the
superagonist complex on the surface of the beads (see Supplemental Figure S3, Appendix
B.2). Protein A-coated beads bound about 8% of the IL-15 complex added, leaving the rest of
the complex in a soluble form in the self-gelling alginate. The Protein A beads themselves did
not cause any activation of BMDCs in vitro, i.e. no upregulation of CD40 (a costimulatory
molecule which is upregulated upon DC maturation) and MHC class II (upregulation of which is
a sign of DC maturation) and no TNF-a (a proinflammatory cytokine) secretion, and the number
of Protein A-coated beads (1 million per gel) injected was determined by keeping the endotoxin
level to be below 0.1EU. More detailed protocols regarding handling of Protein A -coated beads
and IL-15/IL-15Ra complex conjugation to the beads are in Appendix D.6.
4.2.8 Statistical Analysis
All data are shown as mean+S.E. Comparisons of two experimental groups was performed
using two-tailed Mann-Whitney tests using GraphPad Prism software (GraphPad Software Inc.,
La Jolla, CA). Comparisons of Kaplan-Meyer survival curves were made using a log-rank test.
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Figure 4-1: Dendritic cell-loaded alginate gels injected around established melanoma tumors elicit
peritumoral accumulation of CD4+ T-cells but fail to attract CD8 T-cells and have limited therapeutic
efficacy. (A) Schematic of therapeutic approach. (B, C) C57B1/6 mice were inoculated with 5xl04 B 16-ova tumor
cells, and 7 or 14 days later, mice received a single peritumoral injection of either empty alginate matrices or
alginate carrying 2x10 6 activated, ova peptide-loaded DCs. (B) Numbers of gel-infiltrating T-cells recovered 14
days after injections (n = 4-5 mice per group, bars: s.e.m.). (C) B16-ova tumor growth following treatment of 7-
day- or 14-day-established tumors with alginate gels alone (V) or alginate loaded with antigen-pulsed DCs (*)
compared to untreated tumors (0) (n = 10 mice per group).
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4.3 Results
4.3.1 Immunizations with alginate carrying tumor-antigen pulsed DCs.
In Chapter 3 we showed, in non-tumor-bearing animals, that s.c. injection of alginate gels
carrying activated, antigen-loaded dendritic cells elicited priming of na'ive CD8+ T-cells in the
local draining lymph nodes (supported by migration of a small number of DCs from the gel to
the lymph nodes), followed by accumulation of primed antigen-specific T-cells in the gels. To
determine whether DCs delivered in alginate gels could similarly promote accumulation of
antigen-specific T-cells at solid tumor sites, we analyzed the response of established B 16FO
melanoma tumors transduced with GFP and the model antigen ovalbumin (B 16-ova tumors) to
peritumoral injections of activated, ova peptide-loaded DCs in alginate gels. B 16-ova cells were
inoculated s.c. in C57B1/6 recipients and allowed to establish for 7 or 14 days. Mice then
received a single injection of alginate (150 tL) to surround tumors with gels carrying activated
bone marrow-derived dendritic cells loaded with class I- and class II-restricted ova peptides
(Figure 4-1A). Tumor growth was monitored and gels were recovered 14 days after injection for
digestion and analysis of the local immune cell infiltrate accumulating at the tumor site. As
shown in Figure 4-1B, empty alginate gels injected around 14-day-old tumors contained few
CD4 + or CD8+ T-cells. In contrast, gels carrying ova-pulsed, activated DCs elicited a substantial
accumulation of CD4+ T-cells. However, in contrast to responses in healthy mice (197), DC-
loaded gels did not recruit many CD8+ T-cells or endogenous ova-specific CD8+ T-cells to the
peritumoral matrix (Figure 4-1B). Further, the net therapeutic effect of this CD4+-rich T-cell
recruitment to the tumor-surrounding gels was limited: DC-carrying gels elicited a minor
suppression of 7-day established melanomas and were ineffective for treating 14-day established
tumors (Figure 4-1C). Thus, peritumoral gels carrying activated DCs supported the recruitment
of CD4+ T-cells to the matrix, but attraction of CD8+ T-cells was poor and the effect on
established tumor growth was limited.
4.3.2 Sustained release oflL-15 superagonist from alginate gels.
The poor therapeutic effect of DC delivery in tumor-surrounding gels might have reflected
insufficient recruitment of CD8+ T-cells (or other immune effector cells such as NK cells) to the
matrices, failure of peritumoral immune cells to actually infiltrate/attack the surrounded tumor,
suppression of recruited immune cell function at the tumor site, or a combination of these factors.
Thus, we next tested the ability of alginate gels to carry both DCs and immunocytokines, for
slow release of signals that would support CD8 + T-cell accumulation and sustained effector
functions in the tumor-local environment. Recent studies have demonstrated that IL-15 is
capable of reverting anergy in tumor-infiltrating T-cells (200, 201), and that IL- 15/IL-1 5R
chain complexes function as a superagonist (IL-15SA) that potently expands CD8 + T-cells and
NK cell populations in vivo (199, 200, 202, 203). Motivated by these prior studies, we mixed
pre-formed complexes of IL-15 and recombinant murine IL-15Ra-Fc fusion protein in alginate
gels, to obtain sustained release of this cytokine into the tumor environment. In some
experiments, 1x106 protein-A-conjugated 10 ptm-diameter beads were included in the gel, which
immobilized -8% of the IL- 15SA via high-avidity binding of the Fc portion of the IL- 15SA
complex, in an attempt to mimic cellular presentation of IL-15 within the alginate matrix (Figure
S3, Appendix B.2). However, we found that inclusion of the protein-A beads had no detectable
effect on the anti-tumor response at the amount immobilized in these experiments. Self-gelled
alginate released encapsulated IL-15SA over -2 weeks in vitro (Figure 4-2A). In vivo, IL-15SA-
loaded alginate gels injected peritumorally around d14 B 16-ova tumors released cytokine for -5-
7 days (Figure 4-2B). In agreement with prior studies of local cytokine delivery (67, 92), the
level of cytokine detected in the systemic circulation following tumor-local gel release was
substantially lower than levels achieved for the same total quantity of cytokine injected as a
bolus i.p., particularly over the first 4 days following injection (Figure 4-2C). In addition, local
release of IL- 15SA from peritumoral matrices led to peak concentrations of cytokine in the
tumor on day 3 post injection that were -40-fold greater than that achieved by systemic cytokine
injection (Figure 4-2D). Thus, IL-15SA delivered locally from peritumoral alginate ECMs
lowered systemic exposure to the cytokine and greatly concentrated the dose achieved within the
tumor itself compared to i.p. injection.
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Figure 4-2: IL-15SA loaded in alginate matrices concentrates cytokine in the tumor over several
days and lowers systemic exposure relative to systemic injection. (A) 15.9 pg IL-15Ra/Fc was
mixed with 80 pL self-gelling alginate in vitro and release into RPMI medium with 10% fetal calf serum
at 370C was measured over 2 weeks by ELISA. (B-D) 36.7 pg IL-15SA was mixed with 150 pL self-
gelling alginate and injected peritumorally around 14-day-old B16-ova tumors (0). For comparison,
the same quantity of IL-15SA was injected i.p. as a separate group (0). Cytokine present in the gels(B), serum (C), and tumor itself (D) was monitored by ELISA over 7-10 days (n = 3-4 samples per
time-point). Inset of (C) shows the integrated area under the curve quantifying total cytokine exposure
in serum for gel vs. i.p. delivery of IL-15SA over the 10 day timecourse, using IL-15Ra ELISA.
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Figure 4-3: Dendritic cells combined with IL-15SA released from peritumoral alginate matrices
elicit prolonged control of established tumor growth and enhance survival. C57B1/6 mice were
inoculated s.c. with 3x10 4 B16-ova cells and left untreated or received peritumoral injections of 150 pL
alginate gels carrying 2x10 6 antigen-pulsed DCs and/or 36.7 pg IL-15SA on d14 (n = 10 per group). (A)
Tumor growth curves are shown for untreated mice (upper left) or mice treated with alginate carrying
DCs+IL-15SA (upper right). (Lower left) Average tumor growth for mice treated with alginate carrying
DCs+IL-15SA (I) or IL-15SA alone in gels (*), or left untreated (0). (Lower right) Survival of mice
treated with alginate carrying DCs and IL-15SA (0), intratumoral injection of DCs and IL-15SA (0), or
left untreated (0). (B) Tumor growth for untreated mice (0) vs. mice treated with alginate carrying
DCs+IL-15SA (I), i.t. injection of free DCs and IL-15SA (0), s.c. injection of alginate carrying DCs and
IL-15SA on flank opposite the tumor (0), or peritumoral injection of alginate carrying DCs while IL-
15SA is given i.p. (0). (C) Survival of mice left untreated (0) or receiving a single peritumoral injection
on day 14 of alginate carrying IL-1 5SA and 80 pg CpG (X), or receiving two injections of alginate
carrying 36.7 pg IL-15SA on days 14 and 21 (A).
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Figure 4-4: Dendritic cells combined with IL-15SA released from peritumoral alginate matrices
elicit prolonged control of established tumor growth and enhance survival. C57B1/6 mice were
inoculated s.c. with 3x10 4 B16-ova cells and left untreated or received peritumoral injections of 150 pL
alginate gels carrying 2x10 6 antigen-pulsed DCs and/or 36.7 pg IL-15SA on d14 (n = 10 per group). (A)
Tumor growth curves are shown for untreated mice (upper left) or mice treated with alginate carrying
DCs+IL-1 5SA (upper right). (Lower left) Average tumor growth for mice treated with alginate carrying
DCs+IL-15SA (1) or IL-15SA alone in gels (*), or left untreated (0). (Lower right) Survival of mice
treated with alginate carrying DCs and IL-15SA (U), intratumoral injection of DCs and IL-15SA (0), or
left untreated (0). (B) Tumor growth for untreated mice (0) vs. mice treated with alginate carrying
DCs+IL-15SA (1), i.t. injection of free DCs and IL-15SA (0), s.c. injection of alginate carrying DCs and
IL-15SA on flank opposite the tumor (0), or peritumoral injection of alginate carrying DCs while IL-
15SA is given i.p. (0). (C) Survival of mice left untreated (0) or receiving a single peritumoral injection
on day 14 of alginate carrying IL-15SA and 80 pg CpG (X), or receiving two injections of alginate
carrying 36.7 pg IL-15SA on days 14 and 21 (A).
4.3.3 Enhancement of anti-tumor response by IL-15 superagonist in alginate
To test the therapeutic effect of combining DCs and IL-15SA in tumor-surrounding matrices,
14-day established B16-ova tumors were treated with a single peritumoral injection of alginate
matrices carrying ova-pulsed dendritic cells and IL-15SA, and tumor growth was monitored for
21 days. Compared to untreated controls, a single peritumoral immunization with alginate
carrying DCs and IL-15SA substantially retarded tumor growth in the majority of animals, and
enabled mice with tumors smaller than -50 mm2 at the time of treatment to control tumor growth
for at least 1 week following gel injection (Figure 4-3A). Larger tumors also occasionally
showed substantial reductions in size transiently following injection of alginate ECMs (Figure 4-
3A). Comparison of mean tumor sizes in mice receiving gels with DCs+IL-15SA vs. IL-15SA
alone showed that the cytokine played a dominant role in this combination treatment, with DCs
providing only a minor enhancement of the anti-tumor response (Figure 4-3A). Control of
tumor growth required that IL-15SA was released locally from the peritumoral matrix, as gels
carrying DCs and IL-15SA injected on the flank opposite tumors or treatment of mice with
peritumoral gels carrying DCs with IL-15SA given i.p. had a much weaker anti-tumor effect than
injection of the cytokine-loaded synthetic ECMs around tumors (Figure 4-3B). Further, DCs and
IL-15SA in tumor-surrounding matrices were more effective than intratumoral injection of free
DCs and IL-15SA (Figure 4-3B). Control of tumor growth elicited by DC/IL-15SA-carrying
gels was reflected in improved survival compared to each of these alternative treatments (Figure
4-3A and data not shown).
Because preparation of autologous DCs is a laborious and costly process for clinical
implementation, we also explored whether cytokine or immunoregulatory factors alone could
achieve results equivalent to tumors treated with DCs+IL-15SA. We thus tested two alternatives:
first, providing two injections of alginate gel carrying IL-15SA alone, given peritumorally 7 days
apart on days 14 and 21; second, giving a single injection of alginate carrying both IL-15SA and
the Toll-like receptor-9 agonist CpG (204). These gel formulations elicited control over
established B16-ova tumor growth similar to alginate carrying DCs and IL-15SA (Figure 4-4)
and elicited prolonged survival (Figure 4-3C). Thus, optimal selection of immune-supporting
factors for release from the peritumoral matrix enables this treatment to provide prolonged
control of tumor growth without the need for transfer of autologous DCs.
4.3.4 Accumulation of effector cells and reduction of regulatory T-cells by IL-15SA
To begin to understand how IL-15SA alone or in combination with DCs boosted the anti-
tumor response elicited by tumor-surrounding alginate ECMs, we analyzed the impact of IL-
15SA delivery on the recruitment of immune cells at the tumor site following treatment of 14-
day-established B16-ova tumors. As shown in Figure 4-5A, single peritumoral injections of
alginate carrying DCs and IL-15SA did not increase the mean number of CD4 + T-cells localizing
in tumor-surrounding ECMs compared to gels carrying DCs alone, but did amplify accumulation
of CD8+ T-cells by -4-fold. This CD8+ T-cell infiltrate included a population of tumor antigen-
specific cells detected by ova peptide-H-2Kb tetramer staining (Figure 4-5A). We also quantified
the frequency of foxp3+CD4 + regulatory T-cells, DCs, and NK cells attracted to the tumor site by
the optimal DC-free treatment of 2 peritumoral injections of IL-15SA-loaded gels. Untreated
tumors were infiltrated by low frequencies of CD4+ cells, and 30-50% of these cells were foxp3+
(Figure 4-5B). In response to IL-15SA/gel therapy, both the frequency of foxp3+ cells and the
ratio of foxp3 + T-cells to total T-cells (205) within tumors were significantly reduced. In
addition, the frequencies of intratumoral NK cells and DCs were increased 16- and 4-fold
respectively for IL-15SA/gel-treated tumors compared to controls (Figure 4-5B). In separate
experiments, we detected substantial numbers of DCs, NK cells, and CDllc+I-Ab+NKI.1+
'interferon-secreting killer' DCs (IKDCs) (33) in alginate matrices carrying IL-15SA or IL-
15SA+CpG following single gel injections, and a fraction of DCs were GFP +, suggesting that
active acquisition of tumor antigen was occurring in the peritumoral matrices (Figure 4-6). Thus,
immunotherapy with IL-15SA-loaded gels enhanced CD8+ T-cell recruitment to the tumor site,
lowered the relative frequency of regulatory T-cells, and enhanced the frequency of innate
immune cells, all factors expected to augment the anti-tumor response.
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Figure 4-5: Alginate gels
carrying IL-15SA elicit
accumulation of CD8 T-cells,
NK cells, and DCs at the tumor
site, while frequencies of Tr, in
the tumor are reduced.
Established B16-ova tumors were
treated on d14 by peritumoral
injection of empty alginate gels or
gels carrying antigen-pulsed DCs
and/or IL-15SA (n = 4-5 per
group). Gels were recovered on
d28 for analysis. (A)
Representative flow cytometry
analyses of T-cell infiltration in
gels, and mean numbers of CD4*'
CD8 , and antigen-specific ova
tetramer-stained T-cells recovered
from gels. (B) B16-ova-tumor-
bearing mice were left untreated or
received two injections of IL-15SA-
loaded alginate on days 14 and
21. On day 28, tumors and gels
were recovered and frequencies of
CD4foxp3* cells, CD1 lc DCs,
and NK1.1 natural killer cells
were determined.
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4.3.5 Gel-tumor infiltrate correlation.
To understand the relationship between attraction of immune cells to the tumor-surrounding
alginate gels and infiltration of the tumor itself, we next exploited the fact that these synthetic
ECMs are stable in vivo for at least 3 months (197), and examined the cellular composition of the
local immune response when 14-day-old B16-ova tumors were treated with IL-15SA-loaded
alginate gels on days 14 and 21. Enumerating the frequency of CD4 + and CD8+ T-cells in both
the alginate matrix and tumors recovered from mice with a range of tumor burdens on day 28, we
found a strong correlation between the frequencies of CD4+ and CD8+ T-cells accumulated in
peritumoral matrices vs. within the tumor itself (Figure 4-7A). In a similar manner, increased
frequencies of CD 1 c+I-Ab+ dendritic cells (DCs) and NK1.1+ natural killer cells in the alginate
gels coincided with increased frequencies of these cells within tumors (Figure 4-7B, C). These
results suggest that immune cell attraction to the peritumoral matrix either directly promoted
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Figure 4-6: Dendritic
cells and NK cells
accumulate in
peritumoral alginate
ECMs carrying IL-15SA
or IL-15SA and CpG.
C57B1/6 mice were
inoculated with 3x10 4
B16-ova cells s.c. and
tumors were treated on
day 14 by injection of
alginate gels carrying
36.7 pg IL-15SA alone or
with 80 pg CpG. One
group of animals treated
with IL-15SA received a
second alginate injection
on day 21 containing
another dose of 36.7 pg
IL-15SA. Gels were
recovered from animals
21 days after injection
(day 35), digested, and
analyzed by flow
cytometry and cell
counting to quantify
numbers of alginate-
infiltrating dendritic cells
and interferon-secreting
killer dendritic cells (A),
tumor antigen (GFP)-
positive DCs (B), and
natural killer cells (C).
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infiltration of the tumor itself or served as a surrogate indicator of conditions favoring immune
cell accumulation in tumors.
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Figure 4-7: Immune cell accumulation in peritumoral alginate ECMs correlates with
accumulation in tumors. Established B16-ova tumors were treated with 2 injections of IL-15SA-
loaded alginate as in Figure 4-5B. Gels and tumors were analyzed by flow cytometry and shown are
pooled results for gels/tumors taken from the same mice: (A) CD4'TCR + and CD8'TCR + T-cell
frequencies; (B) CD11c+ cells; (C) NK1.1+ cells. Shown is one of 3 independent experiments.
Next, we pooled flow cytometric analyses from 3 independent experiments examining
different protocols of IL-15SA delivery and examined the correlation between the frequency of
immune cells in the peritumoral matrix and the ultimate tumor burden present at day 28 or 35.
The stability of the gels enabled examination of the infiltrates in the peritumoral matrix
irrespective of the final tumor size, and our analysis included samples from mice that completely
eliminated/suppressed tumors following gel therapy. Strikingly, quantification of the frequency
of immune cells recovered from gels vs. final tumor size using data pooled from varied DC/IL-
15SA treatments overlapped in a qualitatively common trend (Figure 4-8). The frequency of
CD4+ and CD8+ T-cells recovered from peritumoral synthetic ECMs sharply declined with
increasing final tumor size, as did the CD4+foxp3:CD4+foxp3+ Teff:Treg ratio (Figure 4-8A).
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(Although the quantitative number of T-cells recovered from gels varied from experiment to
experiment, similar trends were also observed for total cell numbers in individual experiments
(data not shown)). Elevated frequencies of peritumoral matrix-infiltratin T-cells were
recovered from mice when gel therapy regressed tumors as large as -30 mm on the day of
treatment and also when gel treatment prevented slow-growing tumor nuclei from ever
developing (Figure 4-9). In contrast, mice where tumors had reached at least 50 mm 2 or larger
by the end of the experiment uniformly lacked significant T-cell infiltrates in the tumor-
surrounding matrix, even if tumor growth was transiently suppressed early in the experiment
(Figure 4-9). In agreement with the data of Figure 4-7, when we examined leukocyte infiltration
of tumors directly, we found a similar trend, with elevated T-cell infiltration only detected when
therapy kept tumors to sizes <-25 mm2 (Figure 4-8B). This sharply decaying relationship
between T-cell recruitment at the tumor site and tumor growth contrasted with the systemic
response, as tumor antigen-specific CD8+ T-cells were present in the spleens of treated mice at
relatively constant levels irrespective of the sizes of their tumors (Figure 4-8B). Finally, we
examined whether innate components of the immune response exhibited a similar trend of
localization at the tumor site following DC/IL-15SA-gel immunotherapy: The frequencies of
DCs, IKDCs, and NK cells were all sharply elevated by 8-10-fold when tumors were suppressed
to sizes <50 mm2 (Figure 4-8C). Thus, control of tumor growth following gel-delivered
immunotherapy coincided with elevated leukocyte recruitment to the tumor site sustained up to 3
weeks post treatment of tumors with alginate matrices. However, immune cells were present at
only very low frequencies if tumors reached -50 mm2 in size by 2 weeks after gel therapy,
suggesting that the immune response was only sustained under conditions where tumor growth
was strongly suppressed.
Immune responses to tumors are limited by a number of factors developing systemically and
at the tumor site directly. Two limitations in the anti-tumor immune response are insufficient
recruitment of T-cells to tumors (59, 60, 206) and loss of T-cell and innate effector cell functions
in the tumor microenvironment , either due to suppressive factors produced in the tumor site or
via the action of regulatory T-cells (65, 150, 207). In an attempt to both stimulate T-cells and
overcome immunosuppression at the tumor site, here we explored the possibility of local tumor
immunotherapy by 'engulfing' established tumors with injectable synthetic ECMs carrying
antigen-pulsed dendritic cells or immunoregulatory cytokines. The use of the biopolymer
alginate in these studies was motivated by its known biocompatibility and extensive track record
in cell transplantation and tissue engineering applications. Here we explored use of this
synthetic ECM as a carrier for tumor-local delivery of dendritic cells and immunoregulatory
factors, particularly IL-15 in a superagonist form. DCs have been examined in preclinical and
clinical studies as possible cell-based cancer therapeutics capable of breaking tolerance to tumors
(141, 144, 208), while IL-15 has been reported to trigger proliferation of anergic tumor-
infiltrating T-cells (201) and revive effector functions of tumor-resident T-cells (200).
Superagonist IL-15 formed by complexing IL-15 with its high-affinity IL-1 5Ro chain has been
shown to expand CD8 T-cells, NK cells, and NK T-cells in vivo more effectively than IL-15
alone (199, 202), and repeated systemic injections of IL-15SA have been shown to slow tumor
growth in vivo (200). IL-15 can also induce differentiation of monocytes into Langerhans Cell-
like IL-15 DCs (209), and plays a role in maximizing APC function (210). We hypothesized that
by surrounding tumors with DC/IL-15SA-loaded gels, leukocyte accumulation at the tumor site
would be elevated and IL-15SA would be concentrated at the tumor site over several days, while
lowering systemic exposure to the cytokine.
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Figure 4-8: Local leukocyte accumulation in peritumoral alginate matrices is sustained in
peritumoral ECMs, but only when tumor growth is strongly suppressed. Peritumoral alginate gels,
tumors, and spleens were recovered at the end of peritumoral alginate gel therapy experiments performed
as in Figure 4-3 and Figure 4-5, for untreated mice or mice treated with alginate carrying IL-15SA alone,
DCs+IL-15SA, DCs+i.p. IL-15SA, IL-15SA+CpG, or IL-15SA (X2). Gels, tumors, and spleens were
digested and analyzed by flow cytometry. Shown are frequencies of T-cells and the CD4*foxp3"
:CD4*foxp3* Teff : Treg ratio present in gels (A), total T-cells in tumors and ova-specific T-cells in spleens(B), and DCs, 'interferon-secreting killer DCs' and NK cells present in gels (C) as a function of the ultimate
tumor size at d28 or d35 for pooled data from 3 independent experiments.
O
.1
4.
U
a
C.
''V
60
120
V
40-30-A~ 20-
=10
_I-
0 50 100 150 200
final tumor size [mn2]
0
O0
0 0
O O O
R
10 20
[days]
0 10 20 30
[days]
Figure 4-9: Elevated T-cell accumulation in peritumoral alginate matrices is sustained when
alginate gel therapy regresses large tumors or prevents outgrowth of nascent tumor nuclei, but is
completely lacking in animals that transiently regress large tumors. Example individual tumor growth
curves correlated to the frequency of T-cells recovered from peritumoral alginate ECMs at the end of a gel
therapy experiment on day 35. Colored boxes note the T-cell infiltrate detected on day 35 for each
individual tumor growth pattern.
4.4 Discussion
We found that DCs alone in peritumoral alginate ECMs attracted CD4+ T-cells to tumor sites
but elicited weak CD8 T-cell recruitment and had a very limited therapeutic effect on
established B16-ova tumors. However, IL-15SA delivery in the presence or absence of DCs
increased the numbers of CD8 T-cells within alginate matrices (Figure 4-5A and data not
shown), and increasing peritumoral accumulation of T-cells correlated with increased
frequencies of lymphocytes within tumors (Figure 4-7). In contrast to gels carrying DCs alone,
DCs with IL-15SA elicited anti-tumor responses that could control established melanoma growth
for up to a week following a single injection, and enhanced survival of treated animals (Figure 4-
3). This optimal therapeutic response from a single injection was achieved only when IL-15SA
was provided locally at the tumor site and slow-released from the tumor-surrounding matrix.
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Notably, exogenous DCs could be excluded from the therapy by either providing repeated IL-
15SA/gel injections or by combining IL-15SA with Toll-like receptor ligands for slow release in
the tumor environment, substantially simplifying this approach from a clinical standpoint. In
prior studies where IL- 15 SA was used as a stand-alone therapy for treatment of pancreatic
tumors by repeated systemic injection, the enhanced anti-tumor response appeared to be driven
by 'rescued' CD8+ T-cells already resident with tumors rather than by recruitment of new T-cells
to the tumor site (200). Here we found that when IL-15SA was released locally at the tumor
site over several days from the alginate matrix (alone or with DCs), the cytokine promoted
accumulation of T-cells in both the peritumoral matrix and tumor, and reduced the relative
frequency of foxp3 + Tregs. Whether these accumulating T-cells were expanding lymphocytes
already resident in tumors at the time of treatment or represented cells recruited to the site
following gel therapy remains to be determined.
In addition to providing a depot for cell/cytokine localization around tumors, alginate
matrices simultaneously served as stable surrogate ECMs surrounding the tumor site, facilitating
characterization of the immune response developing following tumor cell inoculation and
immunotherapy. Analysis of tumor-infiltrating lymphocytes (TILs) has often been carried out in
an attempt to understand the mechanisms underlying successful immune responses in preclinical
models (24, 27, 59, 73, 205) and has also been used to successfully predict tumor progression
and survival in patients (95, 211, 212). However, TIL analysis is by definition limited to
treatments or timepoints where substantial tumor mass remains. Matrigel has been used as a
synthetic ECM to inoculate tumor cells and analyze early leukocyte infiltration of nascent s.c.
tumor sites (205, 213), but is steadily resorbed over a period of several weeks in vivo (214). Here
we exploited the prolonged stability of alginate ECMs in vivo to analyze the makeup of immune
cells locally recruited to sites where tumors were regressed or where tumor development was
completely suppressed, and compared to treatments that left mice with varying degrees of tumor
burden. This analysis revealed several interesting features of the immune response following
gel-based delivery of dendritic cells and/or IL-15SA: First, when immune cell accumulation at
tumor sites was correlated to final tumor burden for mice receiving different variations in IL-
15SA local therapy, the data followed a common trend. Second, a stark contrast existed between
the immune infiltrate accumulating at tumors regressed to <-50 mm 2 vs. tumors with sizes >50
mm2, even if tumor growth was transiently slowed by IL-15SA treatment. Frequencies of CD8 +
T-cells, CD4 T-cells, dendritic cells, and NK cells were all elevated at the tumor site when final
tumor sizes 21 days after treatment were less than -50 mm 2, but this multifaceted immune cell
recruitment was absent in mice with larger tumor burdens. The lack of T-cell accumulation in
progressing tumors we found here is in line with prior reports in the B 16 melanoma model,
where T-cell infiltration in untreated tumors has been shown to be poor due to defective
expression of adhesion molecules on tumor vasculature (59). However, our studies show that in
addition to suppressed lymphocyte recruitment within the tumor mass itself, T-cells also failed to
accumulate with synthetic ECMs surrounding progressing tumors. Altogether, the data suggest
this local gel therapy elicits an essentially "all or none" response: either established tumors are
steadily regressed (or nascent tumors completely suppressed) coincident with a sustained
multilineage immune cell recruitment at the tumor site, or a complete failure or collapse of this
multifactorial response occurs and tumor growth progresses.
The ultimate goal of local immunotherapy is to generate a systemic immune response
capable of eliminating disseminated tumors and metastases following treatment of an accessible
tumor site. Several recent reports have demonstrated dramatic elimination of established tumors
via i.t. or peritumoral combination therapies with anti-CD40, IL-2, Toll-like receptor ligands,
and/or chemotherapy (42, 188, 215, 216), which were accompanied by systemic immune
responses destroying large distal tumors. The studies reported here suggest that injectable
alginate matrices can provide a strategy for further exploring the potential of local
immunotherapy with IL-15SA or other immunostimulatory factors such as these, while
importantly providing a means to lower systemic exposure and frequency of dosing of these
potent and potentially toxic factors.
4.5 Summary
In this part of the work, we explored the use of injectable self-gelling alginate as synthetic
extracellular immunoplatform to surround tumor sites and carry therapeutic dendritic cells,
cytokines, or other immunostimulatory factors for release in the peritumoral environment.
Immunization of mice bearing 14-day established B 16-ova melanoma tumors with alginate
carrying dendritic cells (DCs) and/or IL-15 superagonist promoted immune cell recruitment to
the peritumoral matrix. Single immunization with IL-15/DC-carrying gels was able to control
the growth of tumors (less than 50mm2 in diameter) for a week or more, encouraging further
improvement and use of sustained IL-15SA delivery as a local tumor therapy. The matrix-based
therapy allowed us to analyze the cellular types that infiltrated the local region surrounding
tumors. Matrix infiltration correlated with tumor infiltration by leukocytes, validating the
significance of analyzing the gel infiltrates to understand the local cellular events that lead to
either failure or control of tumor growth/better survival. Analyses conducted in this chapter
demonstrated the importance of simultaneous, multilineage recruitment of T-cells, dendritic cells,
NK cells, and NK T-cells elicited by treatments to successful treatment or control of tumor
growth over 30 days, irrespective of the type of immunizations applied to the mice.
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Chapter 5
SUMMARY AND
FUTURE CONSIDERATIONS
5.1 Summary of the thesis work
Through this research work, we sought to augment existing cancer immunotherapy strategies
using injectable alginate hydrogels capable of delivering various immuno-factors and to further
understand the mechanisms behind successful vs unsuccessful vaccination against tumors. One
of the cancer vaccines we looked into augmenting was dendritic cell vaccines, in which antigen
loaded dendritic cells (DCs) are injected directly into patients to trigger immune responses. To
achieve these goals, a self-gelling formulation of alginate was developed, obtained by mixing
calcium-loaded alginate microspheres with soluble alginate solution and dendritic cells, a
formulation that rapidly gelled in vivo. Biocompatible polymer solutions that can crosslink in
situ following injection to form stable hydrogels also are of interest as depots for sustained
delivery of therapeutic factors or cells, and as scaffolds for regenerative medicine. In the first
part of this work, injectable self-gelling alginate formulations obtained by mixing alginate
microspheres (as calcium reservoirs) with soluble alginate solutions were characterized for
potential use in immunotherapy. Rapid redistribution of calcium ions from microspheres into the
surrounding alginate solution led to rapid crosslinking and formation of stable hydrogels. The
mechanical properties of the resulting gels correlated with the concentration of calcium reservoir
microspheres added to the solution. Soluble factors such as the cytokine interleukin-2 were
readily incorporated into self-gelling alginate matrices by simply mixing them with the
formulation prior to gelation. Using alginate microspheres as modular components, strategies for
binding immunostimulatory CpG oligonucleotides onto the surface of microspheres were also
demonstrated. When injected subcutaneously in the flanks of mice, self-gelling alginate formed
soft macroporous gels supporting cellular infiltration and allowing ready access to microspheres
carrying therapeutic factors embedded in the matrix.
We then explored the use of these injectable gels for delivery of dendritic cells (DCs), key
immune cells capable of initiating immune responses for vaccination or immunotherapy in
cancer or infectious diseases (140-145). DCs sequestered in alginate gels elicited robust
recruitment of host T-cells and dendritic cells to the matrix, while some of the inoculated DCs
trafficked to the draining lymph nodes. Using an adoptive transfer model to track a defined
population of T cells responding to immunization with antigen-loaded DCs, we showed that
DC/alginate immunization led to recruitment of activated, antigen-specific T cells to the alginate
matrix, in a manner dependent on the presence of the DC. T-cells primed in the native lymph
nodes trafficked to the alginate gels, indicating that this DC-gel immunization is capable of
directing effector T-cells to defined tissue sites in large numbers.
To test the efficacy of these vaccination nodes, to accumulate immune cells at solid tumors or
infection sites in the presence of supporting factors co-delivered by the hydrogel matrix, we used
the B 16-OVA melanoma tumor model. Local therapy of mice bearing 14-day established B 16-
ova melanoma tumors with dendritic cells (DCs) and/or IL-15 superagonist promoted immune
cell recruitment to the peritumoral matrix, and matrix infiltration correlated with tumor
infiltration by leukocytes. Single injections of IL-15/DC-carrying gels controlled the growth of
tumors as large as -30 mm2 for a week or more. The stability of these synthetic matrices in vivo
allowed us to extract the gels and analyze immune cell recruitment to the tumor locale in a
consistent manner irrespective of final tumor size, even when local therapy completely prevented
tumor outgrowth (i.e., no tumor was present at the completion of therapy for analysis of tumor-
infiltrating lymphocytes). This analysis revealed a binary "all or none" immune response
induced by local therapy, with multilineage recruitment of T-cells, dendritic cells, NK cells, and
NK T-cells elicited by treatments that completely prevented tumor outgrowth over 30 days and
much lower levels of all of these immune responders except NK cells elicited by treatments that
failed to eliminate tumors, even if tumor growth was slowed for prolonged times.
5.2 Future Considerations and Possible Applications of Vaccination Nodes
In this work, recruitment and accumulation of effector immune cells at a local peripheral site
were demonstrated. One of the future challenges for the vaccination-node assisted cancer
therapy is to examine whether immune responses can be mounted against distal tumors injected
away from the primary tumor being treated with the gels. Alternatively, re-challenge with the
same tumor cell line or tumor cells expressing the same tumor antigens (i.e. ova-expressing EL4
tumor cell line) in mice successfully treated with vaccination nodes can be tested. Rejection of
distal tumors or protection from tumor re-challenge will indicate successful induction of
systemic immunity and memory, which is one of the biggest advantages and goals of cancer
immunotherapy (as opposed to conventional therapies, as mentioned in Chapter 1). As cytokine
delivery strategies that promote lymphoid tissue-like immune cell accumulation at tumors have
also shown promising anti-tumor effects (157, 158, 217), it will also be interesting to further
explore how the recruitment and self-organization of immune cells occurs in the presence of
additional cytokine signals co-delivered from alginate matrices as a therapeutic strategy. Since
repeated immunizations with alginate containing IL-15 SA showed one of the best tumor
suppression and survival enhancement (Figures 4-3 and 4-4), use of resorbable matrix to allow
for multiple immunization steps can be explored. For example, alginate degradation can be
controlled by selective partial oxidation of uronic units and by combining different molecular
weights of alginate (80-82). We furthermore showed that the use of matrix-based therapy let us
study the effect of cytokines on tumor therapy. This kind of system can be a useful screening
tool for different kinds of candidate factors that need be locally released at a peripheral tissue site,
without going through the problems of loading efficiencies and tuning the release profile. As
nanoparticle and microsphere techonologies improve, the matrix-based delivery system may be
replaced by control-release polymer nano-/microsphere vehicles.
Possible applications of self-gelling alginate as a therapy against cancer include combination
therapy with other immunotherapy strategies in development, especially in the treatment of
resected tumors. The in-situ forming gel can act as a bulk space-filling material at the same time
allowing the creation of local inflammatory milieu that can clean up any residual tumors at the
site. Combination of the vaccination nodes with other strategies that enhance systemic
protection against metastasis and future recurrences will potentially facilitate both local and
systemic treatments of malignant tumors.
In addition to providing a tool for therapeutic benefits, we have demonstrated the use of
matrix-based therapy to study and better understand events that occur locally near or at the tumor
site. Because of the disconnection between systemic anti-tumor response and successful local
tumor rejection observed in our work as well as in many previous studies (59-61, 70), it will be
extremely important and useful to find a connection between the information we can acquire
from systemically circulating cells and factors and the prognosis of the malignancies, especially
since collection of peripheral blood is one of the most common practices used in the clinic to
obtain information from cancer patients (205). Our self-gelling alginate can thus provide a
valuable tool for examininig the biology of local anti-tumor responses even in tumor-free
subjects.
Alginate is a material that has already found applications in a variety of applications including
those outside immunotherapy (74, 78, 84, 103, 104, 218). The in-situ forming self-gelling
alginate formulation introduced in this thesis work offers an alternative method of forming soft
alginate gels and may easily be translated to other soft tissue regeneration and biomaterial
applications, because of its many favorable tissue engineering properties including the ease of
loading different types and dosages of soluble factors as well as different types of cells.
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Appendix A
Preliminary Studies: Injectable Matrix
Material Selection
In order to select an appropriate material for creating vaccination nodes, we first compared
collagen, Matrigel, and alginate as injectable matrices that can deliver
immunomodulatory/immunostimulatory factors to continuously recruit and support desired
effector immune cells as well as counter suppressive effects from the tumor cells. The matrix
should also act as a platform for the recruited cells to fight against the tumor cells. An ideal
matrix must be biocompatible, non-immunogenic, non-cytotoxic, and mechanically stable with
the option of being able to control its biodegradability. Chemokines, cytokines, and other
macromolecules should be able to diffuse through the matrix at rates appropriate for regulating
the immune responses.
In order to choose a matrix or matrices that satisfy these criteria, candidate materials
including collagen, Matrigel, and alginate crosslinked with calcium ions were injected in vivo
with or without factors (lymphoid stromal cells, dendritic cells, CCL21, CXCL 13) to assess their
performance. Their qualitative mechanical properties and integrity in vivo, the types of cellular
infiltrates they attracted at baseline, reproducibility of results, and ease of injections, recovery,
and processing for analyses were compared.
Collagen is a natural biopolymer widely used for cell culture, and it has successfully been
implemented in vitro as a three-dimensional scaffold to study lymphocyte migration in our lab.
It is liquid at 4oC but polymerizes and gels when placed at 370 C. Matrigel is also a natural
biopolymer with composition of basement membranes which resembles the composition of the
reticular fibers in the lymph node. Like collagen, it is fluid at 40 C but gels very quickly upon
heating to body temperature. In addition to the three candidate materials, 50/50 mixtures of
alginate and collagen as well as alginate and Matrigel were compared to examine the effect of
having adhesion molecules in alginate and to let collagen and Matrigel hold the gel together
instead of adding calcium ions.
Results of qualitative comparisons among the matrices are shown in Table S 1; more '+' signs
indicating better performance. Alginate crosslinked with calcium chloride had the best overall
performance, demonstrating good mechanical integrity while in vivo, thus allowing good
recoverability. Preparation for flow cytometry by digestion with enzymes and EDTA to obtain
cell infiltrates was successful, although some cell loss was inevitable. In the preliminary studies,
solution of CaCl2 was used to gel the alginate: the alginate matrix precursor solution, mixed with
factors to be delivered, was injected into the mice first and lw/v% CaCl 2 solution in PBS was
injected as a second step. The use of calcium chloride, however, seemed to increase the number
of inflammatory cell infiltrates recruited to the alginate matrix, but not the distribution of the cell
types recruited compared to when CaCl 2 was not added. Collagen induced very little
inflammation but dissolved in vivo over time and therefore had poor mechanical properties and
poor cell recoverability. Matrigel also exhibited good mechanical integrity in vivo but low
numbers of infiltrating inflammatory cells. Mixtures of alginate and collagen or Matrigel did not
seem to improve any of the properties of the pure matrix alone.
When alginate and Matrigel were compared in their ability to recruit specific cell types, i.e. T
cells, alginate produced the most consistent data. The presence of adhesion molecules in
Matrigel may have therefore been less important for immune cell recruitment and cell retention
at the site than the innate properties alginate possesses as a hydrogel material. More importantly,
Matrigel is an attractive experimental model, but since it is derived of animal origin it cannot be
used in human subjects. Alginate has been safely used in humans before(194-196)and exhibited
many favorable properties for our applications, as described in Chapter 2 of this thesis work, and
alginate was thus chosen as a starting base material for our vaccination node matrix.
Table SI: Qualitative comparison of injectable matrices in vivo. The number of '+'
signs indicates how well each matrix did in each category of assessment.
Recoverability of Cell Recovery for Non-
Mechanical the Matrices Cytometry immunogenicity
integrity
Collagen + + ++ +++
Matrigel ++++ ++++ +++ ++++
Alginate (+CaCl2) +++++ +++++ ++++ +++
Alginate+collagen ++ +++ ++ +++++
Alginate+Matrigel +++ +++ +++ +++
Appendix B
Supplemental Data and Figures
Appendix B.1: T cell recruitment to alginate gels carrying live vs dead mDCs
In order to determine whether the attraction of T cells was a nonspecific inflammatory
response to the presence of a large number of dead cells (i.e. DCs may die inside the gels after
injection), we compared the recruitment of T cells to alginate carrying live DCs (mDCs=
activated, mature DCs), apoptotic DCs, and necrotic DCs. Apoptosis was induced by irradiation
of mature DCs with 254nm UV, using Model UVGL-55 Minerlight lamp, Multiband UV-
254/365nm, 115V-60Hz for 45 seconds in 100 mm2 culture dish. The kill curve for irradiation
with UV is shown in Figure S 1. The viability of the cells did not reach 0 % because the serum in
culture media prevented apoptosis (as told by Patrick Stem from Hynes Lab). Since over-
irradiating the cells seem to have adverse effects on the morphology (and perhaps functions) of
the cells, irradiation time of 45 seconds was chosen for inducing apoptosis. To render the DCs
necrotic, the live, activated, mature DCs were repeatedly freeze-thawed between liquid nitrogen
bath and 37 'C bath for at least 5 times, with an overnight freezing at -80 oC. The cells were 0 %
viable as confirmed by flow cytometry using propidium iodide (PI) live/dead staining.
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Figure SI: Induction of apoptosis by irradiation with UV. Activated, mature DCs were irradiated for
different amounts of time in 100 mm2 culture dishes to assess their viability after additional 24 hrs in
culture at 37 OC. Irradiation time of 45 seconds was chosen for inducing apoptosis in further experiments.
The live, apoptotic, and necrotic DCs were then mixed with self-gelling alginate (2 x 106 cells
per 150 iL of gel; 2 x 106 apoptotic or necrotic DCs had already been aliquoted into individual
eppendorf tubes) and injected into the back flanks of mice as described in chapters 2, 3, and 4.
The gels were explanted 7 days post-injection and were analyzed by flow cytometry. Figure S2
shows that live dendritic cells recruited the highest number of T cells to the injection site,
followed by apoptotic and necrotic DCs/control alginate. Since most of the 'apoptotic DCs'
were still alive at the time of injection and died during the next 24 hrs, the number of T cells that
infiltrated the gels seemed to be proportional to how many live DCs were the gels initially.
These results confirmed that the T cell trafficking phenomenon to the alginate gels was a
consequence of specific actions of live DCs, or any cascade of events that were initiated by live
DCs, and not a result of a nonspecific inflammatory response against dead DCs.
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Figure S2: Recruitment of T cells to alginate gels delivering live vs. dead mDCs. Injection of alginate
with dead mDCs, either apoptotic (induced by irradiation with 254nm UV, using Model UVGL-55 Minerlight
lamp, Multiband UV-254/365nm, 11 5V-60Hz) or necrotic (induced by repeated freeze-thawing of the cells
between -80 OC freezer and 37 OC water bath) cells resulted in inferior T cell attraction compared to
alginate carrying live mDCs, confirming that the T cell attraction was a result of actions of live DCs
delivered in the alginate matrices, and not a consequence of nonspecific inflammatory response against
dead, injected DCs. Control, empty alginate recruited minimal T cells.
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Appendix B.2: IL-15SA immobilization on protein-A coated polystyrene beads
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Figure S3: IL-15SA immobilization on the surface of commercially available protein-A beads. A)IL-15SA was formed by incubating IL-15Ra-Fc and IL-15 together for 30 minutes at 37 OC, followed byincubation with protein A-coated beads to capture the Fc fortions of the cytokine complex to immobilizethe proteins on the bead surface. The IL-15Ra (B) and IL-15 (C) on the bead surfaces could be
detected by flow cytometry using antibodies against the respective proteins. The lifetime of the IL-1 5SAimmobilized on the beads in vitro was shown to be over two weeks (D), while that in vivo was about 6-10days as detected by IL-15 Ra antibody (E).
from the monocyte or dendritic cell surfaces to the other two receptor chains (common IL-15/IL-
2R3 and y chains) on T cell surfaces (219). In order to mimic the presentation of the cytokine
from IL-15Ra chain on cell surfaces, we used Protein A-coated polystyrene beads (-10Om indiameter, well above the size range shown to be optimum for phagocytosis of microspheres
(220)) to capture the Fe portions of Il-15Ra/F chimera proteins, as shown in Figure S3A (seeSection 4.2.7 for Materials and Methods). When 1 x 10 Protein A beads were added to 36.7 jgIL-15SA (31.7 jg IL-15Ra + 5 jg IL-15), Protein A-coated beads bound about 8% of the IL-15
complex, leaving the rest of the complex in a soluble form in the self-gelling alginate. The
number of Protein A-coated beads (1 million per gel) used was determined by keeping the
endotoxin level to be below 0.1EU. This amount of Protein A beads themselves did not cause
any activation of BMDCs in vitro, i.e. no upregulation of CD40 (a costimulatory molecule which
is upregulated upon DC maturation) and MHC class II (upregulation of which is a sign of DC
maturation) and no TNF-a (a proinflammatory cytokine) secretion.
The presence of IL-15 complex on the bead surfaces was confirmed by flow cytometry
(Figures S3B and C), using mouse anti-IL-15Ra conjugated to FITC fluorophore (R&D Systems)
and mouse anti-IL-15 (two-step staining usung biotin-IL-15 (R&D systems) and streptavidin-PE
or streptavidin-APC (BD Biosciences)). Staining solutions consisted of -1.2 pg/mL FITC-anti-
IL-15Ra and -0.6-1 [ig/mL biotinylated anti-IL-15 for the first staining step and -2-5 pg/mL of
streptavidin-fluorophore for the second staining step (-20-30 minutes on ice at each step,
followed by 3X washes with FACS buffer). The lifetime of the immobilized IL-15SA was over
two weeks in culture media in vitro (Figure S3D) at 37 'C, and about -6 days when injected with
self-gelling alginate in vivo (Figure S3E). The beads injected in vivo were harvested back from
the explanted gels the same way cell suspensions were obtained for flow cytometry, as described
in Appendix D.3.
Appendix B.3: IL-15SA release in vivo, detected by two-site IL-15RaIL-15 ELISA
Ref: Figure 4-2
In order to quantify the amount of IL-15SA by ELISA, we used IL-15Ra ELISA kit from
R&D Systems and two-site IL- 15Ra/IL- 15 ELISA (using IL- 5Ra capture antibody and IL- 15
detection antibody from respective ELISA kits). Detection of IL-15 bound to IL-15Ra by IL-15
ELISA kit did not generate signal, possibly because binding of IL-15 to the receptor alpha chain
occludes its epitope for antibody binding (for at least the specific antibodies we used), or because
of conformational changes associated with receptor binding. The technical difficulty in detecting
IL-15SA by specific ELISA to IL-15 has also been reported in other studies (221, 222). The
detection limit of IL-15SA using IL-15Ra ELISA was much lower (highest standard used = 8
ng/mL; lowest standard = 0.125 ng/mL) than that using two-site IL- 15Ra/IL- 15 ELISA (highest
standard used = 50 ng/mL; lowest standard = 0.75 ng/mL). The absolute values of IL-15SA
detected using the two-site ELISA were generally much lower than those (same samples)
detected by IL-15Ra ELISA. It is possible that IL-15 either falls off the receptor chain or
degrades faster than IL- 15Ra (since IL- 15Ra is conjugated to Fc portion of human IgG, its
lifetime may be similar to that of IgG, which could be longer than native IL- 15Ra itself). It is
also possible that the two-site ELISA does not detect the whole complex efficiently, although we
used the same IL-15 complex molecules for standards as the ones used for samples in
experiments so this may not be very likely.
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Figure S4: IL-15SA quantification by two-site IL-15RallL-15 ELISA for in vivo samples presented inFigure 4-2. (A-C) 36.7 pg IL-15SA was mixed with 150 pL self-gelling alginate and injected peritumorally
around 14-day-old B16-ova tumors (0). For comparison, the same quantity of IL-15SA was injected i.p.
as a separate group (0). Cytokine present in the gels (A), serum (B), and tumor itself (C) was monitoredby ELISA over 7-10 days (n = 3-4 samples per time-point).
Figure S4 shows the results of IL-15SA detection in the gels, in the sera, and in the tumors as
detected by two-site IL-15Ra/IL-15 ELISA (as opposed to the results in Figure 4-2 which were
detected by IL-15Ra. Although the absolute values detected were much lower in these cases, the
results confirm that there were sustained release of IL-15SA from the gels in vivo and the tumor
IL-15SA concentration was much more elevated using gels compared to bolus i.p. injections.
The difference in the serum concentration of IL-15SA between gel vs i.p. deliveries were less
pronounced.
Appendix C
Experimental Protocols For In Vitro
Self-Gelling Alginate Formation And
Characterization
Appendix C.1: Alginate particle synthesis
(as modified by A. Winans 09/09/08; edited by Y Hori May 2009)
Ref: Chapter 2, 3, 4
1. Wash probe at homogenizing speed (8x1000/min) with H2 0, isooctane and acetone, in
that order, at 3-5 min. per solvent.
2. Begin stirring 35 mL isooctane in 50 mL beaker at 300 rotations/min. Add 1.5 mL of
Span80 (add 1 mL then 0.5 mL with 1000 1pL pipettor), then 0.5 mL Tween80. Continue
stirring until solution clears.
3. Stop stirring and remove stir bar with larger stir bar. Begin homogenizing at 8x1000/min.
Make sure probe is at least 10 mm from bottom of flask (10-20 mm generally used) and
is centered in the x,y plane. Homogenize for 3 min.
4. Add 400 pL of 1% SLG20 alginate in PBS (wt/vol) dropwise over approximately 20 sec.
Homogenize for 3 more min.
5. Add 25 pL 5% CaC12 (aq) dropwise. Homogenize for 4 more min.
6. Remove alginate solution and pour into 50 mL polypropylene conical tube (purple top).
Centrifuge down in large centrifuge (AllegraTM 6KR centrifuge) at 3,200 rpm (~2060 xg)
for 5 min. Pour off supernatant into organic waste disposal bin.
7. Resuspend pellet with 1 mL isooctane. Add another 30 mL of isooctane and vortex
briefly at high speed.
8. Centrifuge down in AllegraT M 6KR centrifuge again at 3200 rpm (~2060 xg) for 5 min.
Pour off supernatant.
9. Resuspend pellet with 1 mL deionized, distilled (DD) H2 0. Will probably have to mash
the pellet with pipet tip and vigorously pipet to fully dissolve pellet. Transfer to labeled
1.5 mL eppendorf tube.
10. Centrifuge down in benchtop mini centrifuge (VWR) at 11 krpm for 3 min.
11. Pour off supernatant and wash twice more with water (3 times total).
12. Store particles in 1 mL of DD H20.
13. Wash probe as described in #1.
Note: if making two batches in a row, wash the probe twice (go through solvent cycle twice)
before synthesizing a second batch.
Appendix C.2: Measuring Ca2 + release from alginate particles into matrix alginate
(written by A. Winans, 9/26/08; edited by Y. Hori, May 2009)
Ref: Chapter 2
Note: alginate particle to alginate matrix ratios are same as the ones used for in vivo injections
Fluorescence plate reader
1. Put 100 tL of particles solution (around 1 million particles) into a 1.5 mL eppendorf tube.
Make sure particle solution is well mixed before removing aliquot.
2. Centrifuge down at 7 krpm for 30 sec using benchtop mini centrifuge. Remove and
discard supernatant carefully with pipet.
3. Gently vortex particle pellet then sonicate in bath sonicator for 2-3 minutes.
4. Add 160 ipL matrix solution (pre-warm to 37 oC if desired) and pipet thoroughly to
resuspend the particles in matrix.
5. Centrifuge down suspension at desired timepoint at 14 krpm using benchtop mini
centrifuge for 10 min.
6. Carefully remove and collect supernatant (generally there is about 100 tL) and check
under light microscope for particles-there should be none in the supernatant. It is more
time efficient to put 5 ptL of each sample on a glass slide and view them all at once,
rather than using the hemacytometer.
7. Begin 96-well plate preparation: add 20 pL of 25 ug/mL mag-fura-2 in PBS to each well
using multichannel pipet; add 20 tL of concentrated Ca2+ solutions to standards using
PCR tubes and multichannel pipet; add pure SLM20 matrix (to standards) and the
samples one well at a time. Add PBS with multichannel to desired final volume and mix
thoroughly (either 100 tL of 150 pL generally).*
8. Let plate sit in the dark for several hours for the standards and the samples to equilibrate
with the PBS and the dye.
9. Read on plate reader at 340ex/515em and 380ex/515em. Analyze data by taking the ratio
of the 340/380 signals.
Epifluorescent microscope
1. Incubate mag-fura-2 dye in SLM20 matrix solution at a concentration of 25 Ig/mL to
ensure the dye is uniformly spread throughout the matrix (usually incubated for several
hours or overnight).
2. Make Ca 2+ standards (in duplicate) in 8-well Labtek. This is the most important part of
the experiment, since if the standards are not thoroughly mixed, the calibration curve will
not be reproducible. Add concentrated Ca2+ solution to Labtek middle wells followed by
200 [tL of mag-fura-2 infused matrix. Mix thoroughly with single pipet or multichannel
pipet. (I've found mixing two wells at once with the multichannel is better for
reproducibility). Cover in foil and let sit for several hours.
3. Before Ca2+ release, take images of 200 [tL of dye-infused SLM20. Focus
epifluorescence microscope on Labtek edge then move microscope laterally away from
edge toward the center of the Labtek. Take a Z stack to make sure fluorescence is
uniform. Take images at 340 and 380 fura for 10 min.
4. Remove SLM20 in Labtek and mix thoroughly with roughly 1.25 million particles
(normal preparation). Add slurry back to Labtek and continue images for 1-2 hours.
Note: it is assumed the vertical placement of the Labtek and lense does not change
between taking dye-matrix images and dye-matrix-particle images, even though intensity
should be constant across a small z-range for both sets of images anyway. Once the
Labtek is put back on the platform, particles should be visible immediately without
focusing, if the microscope was focused properly for the matrix-dye measurement.
5. Analyze data by taking the average intensity of each collected image and dividing
340ex/380ex intensity measurements.
Appendix C.3: Determination of total Ca 2+ loaded in alginate particles
(written by A. Winans, 9/26/08; edited by Y. Hori, May 2009)
Ref: Chapter 2
1. Take approximately 1 million particles (100 gL of particle solution), centrifuge down at 7
krpm (with benchtop mini centrifuge) for 30 sec and remove and discard supernatant.
2. Sonicate pellet for 1-2 min in bath sonicator.
3. Add 100 pL of 2.5 mM EDTA (0.25 tmoles) and mix thoroughly. Sonicate for 20 min.
4. Add 890 pL of PBS and mix thoroughly. Sonicate for 20 min.
5. Check for presence of particles with light microscope. If particles still present, add
another 10 iL of 10 mM EDTA (0.1 jimoles), sonicate for another 10-20 minutes, and
check again.
6. Prepare plate. Add 20 pL of 25 ug/mL mag-fura-2 dye in PBS to each well. Add
dissolved particle solution to 96-well plate with as little dilution as possible. Prepare
Ca 2+ standards in PBS as well. Let plate sit for 1-2 hours to let dye and Ca2+ equilibrate.
Run plate on reader at 340ex/515em and 380ex/515em.
7. Analyze data by taking the ratio of the 340/380 signals. Assume EDTA binds Ca2+
irreversibly and back-calculate amount of total Ca2+ from total EDTA added and the
amount of free Ca2+ detected by the dye.
Note: the amount of EDTA added is calculated to chelate roughly half of the Ca2+ bound in
particles. If no free Ca2+ is left after dissolving the articles, re-run experiment with less EDTA.
Appendix C.4: QTI Elemental Analysis Sample Preparation
Ref: Chapter 2
1. Alginate particle suspension was centrifuged down and the supernatent removed.
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2. Pellet was resuspended with 300 jtL of 100 mM EDTA solution (disodium EDTA
dihydride).
3. Samples were packaged and sent off.
4. Once QTI received them, each sample was briefly vortexed then sonicated for 30
seconds.
5. 100 tL of sample was added to a nitric acid, then the quantity was diluted to the necessary
sample to be run through the ICP-OES (inductively-coupled plasma - optical emission
spectroscopy).
Appendix C.5: Alginate Labeling With Fluorescent Dye
Ref: Chapter 2
Source: Strand, B. L., Morch, Y. A., Espevik, T. & Skjak-Braek, G. (2003) Biotechnol
Bioeng 82, 386-94.
1. Prepare 2 w/v % alginate solution (i.e. add 12.5 mL PBS to 250 mg sterile Pronova
SLM20 vial) and let it dissolve overnight at 4 oC.
2. Make 18 mM solution of EDC (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide
hydrochloride) and 18 mM sulfo-NHS (N-hydroxysulfo succinimide) in PBS in separate
eppendorf or conical tubes. The volume of the solutions should be such that the total of EDC
and sulfo-NHS solutions will be equal to that of 2 % alginate solution to be labeled. (The
final concentration of EDC and sufo-NHS will both be 9mM).
3. Add the EDC solution to the alginate solution. Vortex.
4. Add the sulfo-NHS solution to alginate solution containing EDC. Vortex.
*Steps 3 and 4 can be done consecutively, i.e. without incubating with EDC for a while.
5. Shake for 2 hrs at room temperature.
6. Add the desired concentration of fluorescent dye to the alginate solution.
*dissolve the dye in a small amount of PBS or H20 first and then add to the alginate
solution:
i.e. 0.32 mM Hilyte Fluor 647 amine (Anaspec, Inc) in PBS
4.5 mM 6-aminofluorescein (Sigma) in 70 % ethanol
*6-aminofluorescein is insoluble in H20, so used 70 % ethanol. The dye
does not dissolve fully, so it becomes a suspension of the dye powder in
ethanol. Vortex well and add as much as you can to the alginate solution.
*Other suggested solvents for 6-aminofluorescein by Sigma are:
0.1 MTris buffer, pH 9.0
0.1 M NaOH
Methanol (0.1 % of dye recommended in ethanol or methanol)
7. Incubate and let the dye and alginate react at room temperature for 18 hrs while
rotating/shaking.
8. Next day: Dialyze the alginate/dye solution with (using 7 kDa MWCO dialysis cassette
from Pierce) against large volumes of PBS (> 1 L) at 4 oC for 3 days or until PBS becomes
clear of freely floating dye.
*Choose the size of cassette such that not much PBS can diffuse into it to dilute out the
final alginate concentration.
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9. Adjust the final volume of the alginate so the alginate concentration will be 0.01 g/mL
(1 % alginate in PBS).
10. Sterile-filter the alginate solution with Sterile Acrodisc Syringe Filters (Pall Corporation)
with 0.45 iL pore size.
11. Store at 4 oC in dark, covered with foil, till use.
*For in vivo use, keep the whole process sterile. Use sterile PBS for dissolving reagents and
for dialysis. Perform as much of the procedure as possible in the TC hood.
Appendix C.6 Endotoxin Level Testing and BMDC Activation Assay (for Alginate
Microspheres and Protein A-Coated Beads)
Ref: Chapters 2 and 4.
LAL Assay
*Follow the manufacturer's instructions (Limulus Amebocyte Lysate QCL-1000, Cambrex).
** Use sterile, flat-bottom 96-well plate (BD Falcon).
** Use "The Jitterbug" (Boekel Jitterbug Microplate Incubator Shaker, Model 130000)
for steps that require the samples to be at 37 'C.
BMDC Activation Assay
1. Culture BMDCs as usual (i.e. isolate from bone marrow and culture in 10 ng/mL GM-CSF
in RPMI + 10 % FCS; feed cells by replacing 800 .iL of culture media with 800 [L of new
media with GM-CSF every other day).
2. On day 5 of culture, add LPS standards (i.e. serial dilutions of LPS from 1 ig/mL down to
1-10 ng/mL) and add bead samples at different concentrations to each well (i.e. 1 x 105 - 1 x
106 beads per well). Have some wells untreated for negative control.
*Prepare all samples and standards in triplicates.
*It is easy to have the concentrated LPS standards and beads in culture media or PBS and
add appropriate amount of standards/samples and add -100 pL per well.
3. Incubate at 37 'C overnight (-18 hrs).
4. Harvest the cells by pipetting vigorously and collecting the cells in conical tubes. Add
-500 .iL cold PBS per well and let stand for - 5 min to further detach cells from the bottom
of the wells and collect the cell suspensions in the same conical tubes.
5. Centrifuge the cells down in conical tubes (-1,300 rpm / -630 xg in AllegraTM 6KR big
centrifuge) for 5 min.
6. Save the supernatants for ELISA (i.e. TNFa, IL-12p70 or IL-12p40, IL-6, etc).
7. Stain the cells for flow cytometry (i.e. CD1 1c, CD40, MHC II/I-Ab).
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Appendix D
Experimental Protocols For In Vivo Gel
Immunization And Analyses
Note: Most of the buffers and reagents were used as described in "Inverse opal hydrogel
scaffolds as lymphoid microenvironments for the study of immune cell migration and
immunotherapy" by Agnieszka Stachowiak (doctoral thesis, 2007), unless otherwise
noted.
*Perform every step of the protocol in a TC hood to keep everything sterile for in vivo use.
Appendix D.1: Tumor Cell Preparation and Inoculation
Ref: Chapter 4
Tumor cell culture
Culture media: high-glucose DMEM (i.e. from Gibco) supplemented with L-glutamine and
10 v/v % FCS.
1. Take frozen vial of tumor cells (B 16-ova) from liquid nitrogen cell bank and thaw it in
the 37 'C water bath for 3-5 min or till the solution completely thaws.
2. Quickly transfer the cells into 20 mL of cold (or room temperature) culture media drop-
wise using a 1 mL pipetteman.
3. Transfer the 20 mL media containing tumor cells into culture flasks (175 cm 2 culture
area).
4. Let the cells settle and grow in the culture flask overnight.
5. Change culture media to one containing 2.5 p.g/mL puromycin to select for GFP-OVA
cells.
6. Continue culturing the cells till they become ~60-70 % confluent.
7. Split cells as necessary until use.
Note: Do not culture the cells for more than one week. They are supposed to lose
aggressiveness after a long culture.
Freezing tumor cells for future use
Freezing media: 90 v/v % FCS + 10 v/v % DMSO
1. Detach asd collect cells from culture flask using trypsin/EDTA (incubate for ~5 minutes
at 37 oC).
2. Centrifuge the cells down at -1200 rpm (~628 xg) with AllegraTM 6KR centrifuge for 3-
5 minutes.
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3. Resuspend the cells in freezing media at about 1.5-2 M cells/mL.
4. Put the cell suspensions in 1-2 mL cryovials and quickly bring them to the -80 'C freezer.
5. Freeze the cells at -80 oC overnight.
6. Transfer the cryovials to liquid nitrogen.
Tumor inoculation
1. Detach and collect the cells from culture flask using trypsin/EDTA (incubate at 37 'C for
3-5 min). It helps to tap the culture flask at the end of the incubation to help detach cells.
2. Centrifuge the cells down at -1200 rpm (-628 xg) with AllegraTM 6KR centrifuge for 3-
5 minutes.
3. Wash the cells with 10-15 mL of HBSS 2-3 X.
4. Resuspend at a concentration of 20,000-100,000 cells in 200 L HBSS per sample.
5. Store the cell suspensions on ice till injections.
*Minimize the time the cells stay in suspension.
6. (At the animal facility) anesthetize the mice with isoflurane.
7. Shave the back flanks of mice.
8. Draw the cell suspensions with 1 mL syringes without needles and then attach 26-30
gauge needles.
9. Subcutaneously inject the cells into the back flank of mice. Wait a few seconds before
withdrawing the needle. Pinch the needle and the skin as you withdraw the needle.
*Try to change needles as often as possible to avoid passing pathogens between
mice.
10. Monitor tumor growth using digital caliper.
Appendix D.2: Gel Immunizations
Ref: Chapters 2, 3, 4
Alginate microsphere pellet preparation
1. Sythesize alginate microspheres (calcium reservoir microspheres) as described in
Appendix C.1, within a week before injections.
2. Pool all the batches of microsphere suspensions together and mix well (alginate
microspheres (1 batch of particles = 1 mL of as-sythesized particles in sterile, distilled,
deionized H20).
3. Dispense 100 jiL of the particle suspension in each eppendorf tube.
4. Centrifuge the particles down at -0.3 x 103 x g for about 2.5 minutes in a table-top mini
centrifuge.
5. Remove the supernatants carefully from each eppendorf tube.
6. Vortex and sonicate the particle pellets for 1-3 minutes.
7. Store at 4 'C till use.
Note: Keep all the procedures sterile.
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Alginate matrix preparation
1. Prepare 1 w/v % Pronova SLM20 alginate solution in PBS (i.e. add 25 mL to the sterile
alginate vial containing 25 mg alginate) and dissolve overnight at 4 oC.
2. Add 3-4 samples worth of matrix solution in each eppendorf tube (prepapre -170 PL per
sample to allow for loss from pipetting and syringes).
3. Add factors to be delivered into the matrix solutions in as little volume as possible (i.e.
concentrated solution of the factors) to avoid dilution of alginate matrix and mix gently
but very well.
* Factors that need be equilibrated overnight, i.e. chemokines, should be mixed the
day before injections.
4. If mixing dendritic cells, harvest and wash the dendritic cells 3X with cold PBS (-50 mL
each time), immediately prior to injections.
5. Keep the alginate matrices containing cells and or other factors on ice till injections.
Note: Keep all the procedures very sterile.
Note 2: When mixing factors into the alginate solution, adjust the concentration so the
desired amount of the factors will be in 150 pL of the matrix solution to be injected (i.e. 2.27
million DCs in 170 jpL matrix).
Gel immunizations
Avertin stock solution: 25 g tribromoethanol (2,2,2 - Tribromoethanol, Sigma) + 15.5 mL
tert-amyl-alcohol (Tert amyl alcohol, 99+%, Sigma). Store stock solution in dark, with
no plastics (it can dissolve certain plastics) and wrapped in aluminum foil at room
temperature or 4 'C for up to one year. The solution crystallizes upon exposure to light.
Avertin injection solution: 60 [tL of stock solution in 5mL of sterile PBS or distilled H20(i.e. in 15 mL polystyrene conical tube). Cover the tube with foil and avoid exposure to
sunlight. Recommended to make fresh solutions before each use, but can keep at 4 oC or
on ice up to one week until use.
1. Anesthesize mice with Avertin (25 pL injection solution per unit gram weight of mouse,
as recommended by the DCM: generally about 300-350 tL of working solution to an
average sized female mouse.) *Do not overdose.
2. Immediately prior to injections, add -165 jtL of the matrix SLM20 solution with or
without desired factors to the calcium microsphere pellet, and pipette gently but very well.
Be careful not to produce any air bubbles.
*Try to minimize volume loss from pipetting (and also from sticking to the sides of
the eppendorf tubes).
3. Draw 150 tL of the mixed gel with 28 gauge insulin syringe.
4. Gently and slowly inject the gel subcutaneously, surrounding tumors.
*May need to move and change injection directions to get the gels to go around tumors.
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Appendix D.3: Gel and Tumor Isolation for Flow Cytometry Analyses and ELISA
Ref: Chapters 3 and 4.
Tumor and gel isolation from the mice
*Prepare 12-well culture plates with 500 iL PBS or RPMI (with or without 10 % FCS) in
each well. Bring the plate on ice to the animal facility.
1. Euthanize -2-4 mice at a time (to avoid keeping the mice dead for too long before
isolation to keep cells as fresh as possible and also since the tissues harden up after death).
2. Spray the mice well with quatricide solutions and pin the mice down to the dissection
board using 26 gauge syringe needles (one arm, two legs).
3. Cut the skin around the tumors and gels with dissection scissors. Leave as large margins
as possible around the tumors and gels, but careful not to mess up the inguinal lymph
nodes if isolating the lymph nodes as well.
4. Gently snip through the border of the tumors/gels and the tissues to separate them from
the muscles first. The gels and the tumors are still attached to the skin.
5. Open the skin flap and pin them down so the skin is tightly spread over its tail.
6. Gently separate the gels and or tumors from the skin and from each other.
7. Place the explanted gels, tumors, and any other tissues into 500 [L PBS or RPMI (10%
FCS) in each well of a 12-well tissue culture plate.
8. Keep the tissue culture plate on ice till all the samples have been isolated.
Tumor and gel digestion for flow cytometry
Digestion solution: 0.14-0.28WO/mL Liberase Blendzyme 3 in PBS or RPMI (10 % FCS)
FACS buffer: HBSS (calcium and magnesium-free) + 0.1 w/v % sodium azide (NaN 3) +
1.0 w/v % bovine serum albumin (BSA, fraction V). Store up to 1 year at 40 C.
1. Add the digestion solutions to the explanted samples so that the total final solution
volume will be 1 mL.
2. Chop the samples up in small pieces. Wash the fragmentns and solutions stuck to the
scissors and forceps (still keeping the final solution volume to be 1 mL).
3. Add 100 [L of 10 mg/mL alginate lyase to gel samples.
4. Shake and incubate at 37 'C for 15-20 minutes.
5. Add 300 iL of 0.02% EDTA to gel samples.
6. Homogenize the samples using the backs of 1 mL syringe pistons in 40 [pm cell strainer
and pass the cells through the strainer mesh with 9 mL of PBS or RPMI (10 % FCS) into
polystyrene 50 mL conical tubes. The total volume of cell suspension collected will be
-10 mL.
7. Centrifuge the cell suspensions down at 1,300 rpm (-630 xg) in the AllegraTM 6KR
centrifuge.
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8. Resuspend the cells in FACS buffer containing purified CD16/CD32 antibodies to block
nonspecific binding sites and transfer the samples to V-bottom FACS staining 96-well
plates. Wait 10 minutes.
9. Stain the cells with fluorophore-conjugated antibodies for 20-30 minutes on ice. (i.e. 1.2
pL of PE-antibody, 2.4 jtL of FITC-antibody, and 1.5 tL of APC-antibody in 100 [tL
total staining solution, for antibodies from BD Biosciences).
10. Wash the cells with FACS buffer 3X (total volume in each well -200 tL during washes).
11. Resuspend the cells in 70-100 gL FACS buffer and transfer them to FACS tubes.
12. Add PI (propidium iodide) to desired samples at 1.27 pg/mL final concentration to stain
for dead cells.
13. Prepare calibration standards by adding known number of cells in the same amount of
buffer used for samples. Do serial dilutions to have about 5 different concentrations of
cells. *The actual number of cells and the count the FACS machine recorded can be
used to calculate the'FACS reading error.'
14. Run the whole tubes on FACS machine (usually used FACSCalibur).
Note: When running flow cytometry on protein-A coated beads, with or without IL-15 complex
conjugated to them, use FACS buffer supplemented with 0.05 v/v % Tween 20.
Tumor and gel digestion for ELISA
ELISA buffers:
Reagent diluent: 1 w/v % BSA in PBS, pH 7.4 (i.e. 10 g BSA in IL PBS)
Block buffer: 1 w/v % BSA + 0.1 w/v % NaN3 in PBS.
Stop solution: 1 M (2N) H2SO 4 in H20
T-Per Tissue Protein Extraction Reagent (Pierce, Rockford, IL) supplemented by Halt
Protease Inhibitor Cocktail (Pierce): 1.5 mL T-Per Reagent + 20 jtL Halt Protease
Inhibitor + 500 gtL PBS (PBS is the original solution used for storing samples after
isolation). *add 100 gtL of 10 mg/mL alginate lyase for gel digestion.
1. Collect samples in eppendorf tubes containing 500 tL PBS on ice. Chop the samples up
in small pieces as you harvest them from mice.
2. Add digestion solutions to the tubes.
* can use either the collagenase/Blendzyme 
-based digestion solution as described in the
"tumor and gel digestion for flow cytometry" section (add the digestion solution so that
the final volume in the eppendorfs will be 1 mL), or use the T-Per reagent supplemented
with Halt Protease Inhibitor (add 500 tL to each eppendorf tube).
3. Add 100 tL of 10 mg/mL alginate lyase to gel samples only (final lyase concentration =
1 mg/mL).
4. Vortex the samples quickly and immediately homogenize the samples using the backs of 1
mL syringe pistons in 40 ptm cell strainer. Pass the cells through the strainer mesh with
the rest of the digestion solution (1 mL) into polystyrene 50 mL conical tubes. The total
volume of cell suspension collected will be -2 mL.
* adjust the final volume collected, depending on the concentration of the protein you are
trying to detect using ELISA.
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5. Centrifuge the collected supernatantns down at 2-3,000 rpm (-1,400-2000 xg) in the
AllegraTM 6KR centrifuge.
* if doing flow cytometry on the cells with the same samples, centrifuge at 1,300 rpm
instead.
6. Carefully collect the supernatants, not to pipet the cells or any other debris, and store in
eppendorf tubes.
7. Perform ELISA according to the manufacturer's instructions (i.e. R&D Systems).
8. Read the plate with absorbance plate reader (kl - k2; ~1 = 450 nm; k2 = 540 nm).
Note: Always have 'digested' and 'non-digested' controls using soluble proteins (i.e. IL-15
complex) to calculate how much loss digestion incurs to the samples. Correct the values
obtained with ELISA with loss factors to obtain actual values.
Note 2: Some cytokines (i.e. IFN-y, IL-15) seem very sensitive to collagenase-based digestion.
They seem to degrade quickly over time during storage (even at -20 oC), so use them right away
if possible. If storing, have a digested and stored soluble control of the protein (treated exactly
the same way as the samples are).
Appendix D.4: Intracellular Foxp3 Staining
Ref: Chapter 4
Live/Dead Fixable Dead Cell Stain Kit: from Invitrogen, catalogue # L23102
Anti-mouse/rat foxp3 staining kit: from eBioscience, catalogue # 72-5775-40
1. Digest and prepare single cell suspensions from explanted gels, tumors, and/or tissues as
described in steps 1-7 of "Tumor and gel digestion for flow cytometry" in Appendix D.3.
2. Transfer the cell suspensions from conical tubes to V-bottom FACS staining 96-well plates.
3. Instead of resuspending the cell suspensions in FACS buffer for Fc-blocking with
CD16/CD32, resuspend the cells with PBS.
3. Wash the cells 1-2X with PBS by centrifuging them down at 1,300 rpm (-630 xg) in the
AllegraTM 6KR big centrifuge.
4. Reconstitute live/dead fixable dye in DMSO (i.e. one vial in 50 pL DMSO), vortex well
and leave on ice till use.
5. Add 10-25 pL of the dye stock in 10 mL PBS (suggested from manufacturer's protocol =
1 iL in 1 mL). *used -25 L for the data shown in this thesis work.
6. Use the solution from step 5 to resuspend the cells with the live/dead fixable dye (100 1L
each well). Leave for 30 min on ice, in dark.
*It is important not to have any amine-containing groups (i.e. BSA, FCS) in the cell
suspensions for live/dead stains.
7. Wash 1-2X with PBS.
8. Fix cells with 100-200 [tL of Fixation/Permeabilization Buffer (i.e. 6 mL Fix/Perm
Diluent + 2 mL Fix/Perm Concentrate) and leave for 30 min- 18 hrs in dark. *did -4 hrs for
the data shown in this thesis work.
9. Centrifuge the cells down and resuspend and wash them 1-2X with Permeabilization
Buffer (i.e. 1 mL Permeabilization Buffer + 9 mL distilled H20). *can probably proceed to
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the next step immediately, but incubated in Permeabilization Buffer overnight (-18 hrs) at 4
'C for the data shown in this thesis work.
10. Next day: block the cells with purified anti-mouse CD 16/32 for 10 min on ice or at room
temperature.
11. Add fluorochromes (i.e. -1 pg/mL PE-foxp3, -10 pg/mL FITC-TCR3, -1.5 pg/mL in
100 gL final volume of staining solution) to the cells and incubate on ice for 30 min.
12. Wash 2X with Permeabilization Buffer (-185 pL each time).
13. Resuspend in FACS buffer and transfer to FACS tubes.
14. Run flow cytometry.
Appendix D.5: IL-15/IL-15Ra Complex Formation
Ref: Chapter 4
IL-15 used: R&D Systems Catalog # 447-ML (with or without carrier)
Most of the experiments used Lot # FCL1408071, endotoxin level = 0.7 EU/pg
The last experiment with 2X alg+IL-15SA immunization and foxp3 staining used
Lot# FCL1408102, endotoxin level = 0.7 EU/pg
IL-15Ra used: R&D Systems Catalog # 551-MR (with or without carrier)
Lot# DKJ1208081, endotoxin level = 0.000364 EU/jig
Lot# DKJ1008041, endotoxin level = 0.0669 EU/pg
1. Reconstitute IL-15Ra/Fc (100 pig/vial) with 50 piL PBS (or 0.1 w/v %BSA in PBS for
carrier-free IL-15Ra or IL-15) for the final concentration of 2 mg/mL.
2. Using the 2 mg/mL IL-15Ra/Fc solution from step 1, reconstitute IL-15 (i.e. 31.7 pL IL-
1 5Ra/Fc solution to each vial of IL-15 containing 10 pg of the protein.
3. Soak the bottom of the vials in 37 'C water bath to warm up the vials.
4. Spray the vials and any container you will use to incubate the IL-15 complex with 70 %
ethanol.
5. Incubate the IL-15 complex vials at 37 'C (tissue culture incubator) for 30 min.
6. Take out the vials from the incubator and combine all the IL-15 complex solutions from
different vials into one. This is to make sure all the IL-15 complexes are homogenous and
uniform, especially if using different lot numbers for the proteins (containing different
endotoxin levels).
6'. Rotate or shake at 45 min at room temperature.
7. Store at 4 oC overnight (-16-18 hrs), covered in foil and rotating or shaking.
*Steps 6' and 7 were done to be consistent with IL-15 complex conjugated to protein A
coated beads, which underwent 45 min incubation at room temperature followed by an
overnight incubation at 4 'C (as described in Appendix D.6). The last two steps can be
omitted and the IL-15SA solutions can be used right away if no additional steps are
needed for conjugation, etc.
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Appendix D.6: Protein A Bead Sterilization And Immobilization of IL-15SA on the
Bead Surfaces
Ref: Chapter 4, Section 4.2.7
Bead sterilization
Sterile filtered 70 % ethanol: filter 70 % ethanol from tissue culture room using Sterile
Acrodisc Syringe Filters (Pall Corporation) with 0.2 pm pore size.
0.05 v/v % Tween 20 in H20: sterile filter before use, store at 4 oC.
Sterile H20: sterile filter milliQ deionized, distilled H2 0 before use
FACS buffer with 0.01-0.05 v/v % Tween 20: add appropriate amount of Tween 20 to
FACS buffer
1. Aliquot the amount of Protein A-coated beads needed into an eppendorf tube.
2. Wash the beads 2X with sterile H20 (milliQ) by centrifuge (2.5-4 min at 3-7,000 xg).
3. Add 500-1,000 pL of 70 % ethanol to the tube, vortex, and immediately centrifuge it
down in the bench-top mini centrifuge for 2.5-3 min at 3-7,000 xg.
4. Discard the 70 % ethanol supernatant by flipping the tube.
5. Add 1 mL of 0.05 % Tween 20 in H20, vortex, and centrifuge it down.
6. Wash IX or 2X with sterile H20.
* the point here is to get rid of as much Tween 20 as possible to have just he minimum
amout of it needed to keep the protein A beads from sticking to the sides of the
eppendorfs. We want to avoid having too much Tween 20 because it could potentially
affect the immune response (i.e. act as adjuvant) in vivo. Keep in mind that there will
be another 'wash' or 'centrifuge' step before conjugating IL- 15/IL- 15Ra.
7. Keep suspended in H20 and stored at 4 C until use. It is recommended to use the beads as
freshly sterilized as possible.
Note: Whenever the beads start sticking to the walls of the eppendorfs or do not pellet well, add
0.05 % Tween 20 in H20.
Conjugation to IL- 15/IL- 15Ra
1. Centrifuge and pellet the sterilized protein A-coated beads.
2. Add IL-15/IL-15Ra complex as prepared in Appendix D.5 to the eppendorfs containing
bead pellets. Do not touch or pipet the beads up and down (because a lot of them can stick to
the pipet tips).
3. Vortex the beads gently.
4. Rotate or shake at room temperature for 45 min.
5. Cover with foil and rotate or gently shake overnight (-16-18 hrs) at 4 oC.
6. Before use: centrifuge down the beads and gently vortex them so the beads disperse into a
suspension (and not stay in pellet) but they do not splash up and stick to the sides of the
eppendorfs.
* If incorporating into self-gelling alginate, pipet the beads into the alginate precursor
solution and then vortex the whole solution instead of pipetting (to avoid losing gels and
beads from pipetting).
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